var title_f11_18_11552="Purulent drainage";
var content_f11_18_11552=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Purulent drainage following creation of a cystgastrostomy in a patient with a pancreatic pseudocyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 341px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view following balloon dilation revealing purulent drainage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Raj J Shah, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_18_11552=[""].join("\n");
var outline_f11_18_11552=null;
var title_f11_18_11553="Idiopathic hemosiderosis CT";
var content_f11_18_11553=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Idiopathic pulmonary hemosiderosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High resolution computed tomographic (HRCT) scanning of the chest in a 55 year old woman with idiopathic pulmonary hemosiderosis and daily hemoptysis for 6 months. There are several areas of ground- glass opacification (arrows) in both lungs, indicating alveolar filling.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nils Milman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_18_11553=[""].join("\n");
var outline_f11_18_11553=null;
var title_f11_18_11554="Patient information: When you have depression and another health problem (The Basics)";
var content_f11_18_11554=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/57/12179\">",
"         Patient information: Depression (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/6/24675\">",
"         Patient information: Medicines for depression (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/36/27202\">",
"         Patient information: When you have multiple health problems (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/6/13413\">",
"         Patient information: Depression in adolescents (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/41/20116\">",
"         Patient information: Depression in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/21/29013\">",
"         Patient information: Depression treatment options for adolescents (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/24/21894\">",
"         Patient information: Depression treatment options for adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: When you have depression and another health problem (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/when-you-have-depression-and-another-health-problem-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1673017045\">",
"      <span class=\"h1\">",
"       Is depression common among people with other health problems?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, people with the following medical conditions often have depression, too:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Heart disease or a history of stroke",
"       </li>",
"       <li>",
"        Diabetes",
"       </li>",
"       <li>",
"        Chronic obstructive pulmonary disease (also called &ldquo;COPD&rdquo;)",
"       </li>",
"       <li>",
"        Arthritis or other causes of ongoing pain",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1673017062\">",
"      <span class=\"h1\">",
"       Does having a medical condition make people depressed or the other way around?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Nobody knows. For now all that scientists can say for sure is that people with ongoing medical problems are more likely than healthy people to get depressed.",
"     </p>",
"     <p>",
"      People with medical problems can get depressed because:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        They have physical limitations",
"       </li>",
"       <li>",
"        They are afraid they might die or have a health crisis, such as a heart attack",
"       </li>",
"       <li>",
"        They have to spend a lot of time, energy, and sometimes money managing their illness",
"       </li>",
"       <li>",
"        They have pain, trouble breathing, or other symptoms that make it hard to enjoy life",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      To make matters worse, having depression makes it hard for people to do the things they need to do to manage their medical conditions. For example, depression can make it hard to:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Remember to take your medicines or go to your doctor appointments",
"       </li>",
"       <li>",
"        Do physical activities or stay active, which is often recommended for better health and to overcome depression",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1673017077\">",
"      <span class=\"h1\">",
"       How do I know if I am depressed?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Depressed people feel down most of the time for at least 2 weeks. They also have at least 1 of these 2 symptoms:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        They no longer enjoy or care about doing the things they used to like to do.",
"       </li>",
"       <li>",
"        They feel sad, down, hopeless, or cranky most of the day, almost every day.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Depression can also make you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Lose or gain weight",
"       </li>",
"       <li>",
"        Sleep too much or too little",
"       </li>",
"       <li>",
"        Feel tired or like you have no energy",
"       </li>",
"       <li>",
"        Feel guilty or like you are worth nothing",
"       </li>",
"       <li>",
"        Forget things or feel confused",
"       </li>",
"       <li>",
"        Feel hopeless and think about death or suicide",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you think you might be depressed, see your doctor or nurse. Only someone trained in mental health can tell if you are depressed.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1673017094\">",
"      <span class=\"h1\">",
"       What can I do if I have depression and another medical problem?",
"      </span>",
"      &nbsp;&mdash;&nbsp;For starters, do not assume that being depressed is a normal part of being sick. It&rsquo;s normal to be sad sometimes when you are sick, but depression is more serious and long-lasting than that. If you think you are depressed, mention it to your doctor or nurse, and look into treatment.",
"     </p>",
"     <p>",
"      Also, make sure that all your doctors and nurses know about all your health problems, including your depression. That way, they know to keep all of those problems in mind when choosing treatment for you. If you have heart disease and need medicines for depression, for example, the doctor treating your depression will need to choose depression medicines that are safe for people with heart disease.",
"     </p>",
"     <p>",
"      Finally, if you are having a hard time dealing with your illness, think about joining a support group for people with the same illness. Being part of such a group can help you feel less alone. Plus, it can help you learn skills from other people who have been through what you are going through.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1673017109\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=see_link\">",
"       Patient information: Depression (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/6/24675?source=see_link\">",
"       Patient information: Medicines for depression (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/36/27202?source=see_link\">",
"       Patient information: When you have multiple health problems (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"       Patient information: Depression in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"       Patient information: Depression treatment options for adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=see_link\">",
"       Patient information: Depression in adolescents (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/21/29013?source=see_link\">",
"       Patient information: Depression treatment options for adolescents (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/18/11554?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83813 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-7288C09AE7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_18_11554=[""].join("\n");
var outline_f11_18_11554=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1673017045\">",
"      Is depression common among people with other health problems?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1673017062\">",
"      Does having a medical condition make people depressed or the other way around?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1673017077\">",
"      How do I know if I am depressed?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1673017094\">",
"      What can I do if I have depression and another medical problem?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1673017109\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=related_link\">",
"      Patient information: Depression (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=related_link\">",
"      Patient information: Depression in adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=related_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/21/29013?source=related_link\">",
"      Patient information: Depression treatment options for adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=related_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/6/24675?source=related_link\">",
"      Patient information: Medicines for depression (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/36/27202?source=related_link\">",
"      Patient information: When you have multiple health problems (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_18_11555="Tetanus immune globulin (human): Patient drug information";
var content_f11_18_11555=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tetanus immune globulin (human): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/293?source=see_link\">",
"     see \"Tetanus immune globulin (human): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/46/40676?source=see_link\">",
"     see \"Tetanus immune globulin (human): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F226065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      HyperTET&trade; S/D",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F226066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      HyperTET&trade; S/D",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691529",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat tetanus infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tetanus immune globulin, thimerosal, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697275",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have IgA deficiency, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11880 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-6FA69E1D15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_18_11555=[""].join("\n");
var outline_f11_18_11555=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226065\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226066\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012429\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012428\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012433\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012434\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012436\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012431\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012438\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/18/293?source=related_link\">",
"      Tetanus immune globulin (human): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/46/40676?source=related_link\">",
"      Tetanus immune globulin (human): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_18_11556="Padding short arm cast";
var content_f11_18_11556=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Padding for a short arm cast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 355px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Padding is applied over the stockinette in a distal to proximal direction. Each layer should overlap the preceding layer by approximately 50 percent. Additional padding should be placed over bony prominences.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Titus, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_18_11556=[""].join("\n");
var outline_f11_18_11556=null;
var title_f11_18_11557="Streptozocin: Patient drug information";
var content_f11_18_11557=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Streptozocin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/30/9702?source=see_link\">",
"     see \"Streptozocin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F223269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zanosar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F223270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zanosar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700694",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may have unsafe effects on the bone marrow. The bone marrow may not be able to make cells found in the blood as well as it used to.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700775",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause very bad or life-threatening kidney problems. It may cause loose stools, liver problems, or very bad upset stomach and throwing up. You will be closely watched by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug can cause cancer in animals. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692009",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pancreatic cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692146",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given to you for other reasons. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702958",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to streptozocin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4194404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may interact with other drugs or health problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4194405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2858939",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid driving and doing other tasks or actions that call for you to be alert until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194398",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause harm to the unborn baby if you take it while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4186184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor if any of these side effects or any other side effects bother you:",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4186185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these side effects:",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4199664",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of kidney problems like unable to pass urine, change in the amout of urine passed, blood in the urine, or a big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4192387",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of liver problems like dark urine, feeling tired, not hungry, upset stomach or stomach pain, light-colored stools, throwing up, or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mood changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause tissue damage if the drug leaks from the vein. Tell your nurse if you have any redness, burning, pain, swelling, or leaking of fluid where the drug is going into your body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at",
"       <a href=\"file://www.fda.gov/medwatch\" target=\"_blank\">",
"        file://www.fda.gov/medwatch",
"       </a>",
"       .",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699689",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may report side effects to Health Canada's Canada Vigilance Program at 1-866-234-2345.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696083",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug as ordered by your doctor. Read and follow the dosing on the label closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F16342271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F16342272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check with your pharmacist about how to throw out unused drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11428 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.97.94.19-4FC0FD0E7D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_18_11557=[""].join("\n");
var outline_f11_18_11557=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223269\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223270\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022252\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022254\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022253\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022258\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022259\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022261\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022256\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16342271\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16342272\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022263\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/30/9702?source=related_link\">",
"      Streptozocin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_18_11558="Urine anion and osmolal gaps in metabolic acidosis";
var content_f11_18_11558=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Urine anion and osmolal gaps in metabolic acidosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/18/11558/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/18/11558/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/18/11558/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/18/11558/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/18/11558/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/18/11558/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/18/11558/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the urine anion gap and urine osmolal gap may be helpful in the evaluation of patients with a normal anion gap (hyperchloremic) metabolic acidosis by providing an estimate of urinary ammonium (NH4) excretion (",
"    <a class=\"graphic graphic_table graphicRef77464 \" href=\"UTD.htm?38/0/38924\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11558/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The normal renal response to metabolic acidosis is to increase urinary NH4 excretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link\">",
"     \"Approach to the adult with metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical use of the urine anion and osmolal gaps will be reviewed here. Issues related to use of the serum anion and osmolal gaps are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=see_link\">",
"     \"The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41430?source=see_link\">",
"     \"Serum osmolal gap\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H529595797\">",
"    <span class=\"h1\">",
"     BRIEF OVERVIEW OF RENAL ACID EXCRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ingestion of a typical Western diet generates approximately 50 to 100 meq of hydrogen ions (nonvolatile acid: ie, acids other than CO2) per day. To maintain acid balance, these hydrogen ions must be excreted in the urine in a process that includes the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12762?source=see_link\">",
"     \"Chapter 11A: Renal hydrogen excretion\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reabsorption of filtered bicarbonate, since bicarbonate loss is equivalent to the generation of hydrogen ions.",
"     </li>",
"     <li>",
"      Excretion of the daily nonvolatile acid load. Only trivial amounts of free hydrogen can be excreted since, at a urine pH of 4.5, the free hydrogen ion concentration is less than 0.04",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      Thus, free hydrogen ions are either bound to buffers (such as phosphate) or to ammonia (NH3) to form ammonium (NH4).",
"     </li>",
"     <li>",
"      The main adaptive renal response to metabolic acidosis is to increase hydrogen ion excretion in the form of NH4. In patients with severe metabolic acidosis and normal renal function, NH4 excretion can increase from the normal value of 30 to 40",
"      <span class=\"nowrap\">",
"       meq/day",
"      </span>",
"      to as much as 200 to 300",
"      <span class=\"nowrap\">",
"       meq/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11558/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. NH4 is usually excreted with Cl but is sometimes excreted with other anions such as ketoacid anions, hippurate, or HCO3.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     URINE ANION GAP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calculation of the difference between the urine sodium (Na) plus potassium (K) concentration and the urine chloride (Cl) concentration can be helpful in patients with various acid-base disorders. This calculation has been called the urine anion gap (UAG):",
"   </p>",
"   <p>",
"    UAG (in",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    &nbsp;= &nbsp;Urine (Na &nbsp;+ &nbsp;K &nbsp;- &nbsp;Cl)",
"   </p>",
"   <p>",
"    Some clinicians find the term \"urine anion gap\" confusing and prefer to call this measurement the \"urine cation gap\" or the \"urine net charge\". In this document, we use the term urine anion gap or UAG.",
"   </p>",
"   <p>",
"    It is important to understand that the formula for the UAG is different from the formula used to calculate the serum anion gap. The serum anion gap is the difference between the serum sodium and the sum of the serum chloride and bicarbonate concentrations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link&amp;anchor=H8#H8\">",
"     \"Approach to the adult with metabolic acidosis\", section on 'Serum anion gap and differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When individuals ingest a typical Western diet, the quantity of sodium and potassium absorbed by the gastrointestinal tract usually exceeds the quantity of absorbed chloride. Thus, under normal circumstances, the sum of excreted urine Na and urine K is greater than the amount of excreted urine Cl. The UAG therefore has a",
"    <strong>",
"     positive",
"    </strong>",
"    value (between 20 and 90) in healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11558/abstract/4,8\">",
"     4,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in patients with metabolic acidosis, the excretion of NH4, usually with Cl, increases the urine Cl concentration. In such settings, urine Cl usually exceeds the sum of urine Na and urine K, resulting in a",
"    <strong>",
"     negative",
"    </strong>",
"    UAG [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11558/abstract/1,2,4,5\">",
"     1,2,4,5",
"    </a>",
"    ]. The value of the UAG can provide an indirect estimate of urinary NH4 excretion in these patients.",
"   </p>",
"   <p>",
"    Urine NH4 is difficult to measure directly in clinical settings, and therefore the UAG is a surrogate for this measurement. Although some investigators have advocated using equations to convert the value of the UAG into an estimated urine NH4 concentration, there is substantial variability in these methods. Thus, it is probably best to use the UAG as a qualitative rather than quantitative surrogate for urine NH4 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11558/abstract/1,3-5,8,9\">",
"     1,3-5,8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A positive UAG is consistent with low or normal NH4 excretion. As an example, patients who have metabolic acidosis associated with impaired NH4 excretion (such as a distal renal tubular acidosis) will have a positive UAG.",
"     </li>",
"     <li>",
"      A negative UAG is consistent with increased NH4 excretion (ie, greater than 80",
"      <span class=\"nowrap\">",
"       meq/L).",
"      </span>",
"      As an example, the UAG generally falls to a range between -20 and -50",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in patients who develop metabolic acidosis as a result of diarrhea.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193592503\">",
"    <span class=\"h2\">",
"     Uses of the urine anion gap",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of distal RTA, hypoaldosteronism, and chronic kidney disease can usually be made from the history, serum chemistries, and the urine pH [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11558/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Distal RTA is characterized by a urine pH that is persistently above 5.5 despite metabolic acidosis; the normal renal response to metabolic acidosis is to reduce the urine pH to 5.3 or less. Hypoaldosteronism causes hyperkalemia; the urine pH may or may not be below 5.3. Chronic kidney disease is recognized by a substantial reduction in estimated glomerular filtration rate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link&amp;anchor=H5#H5\">",
"     \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41353?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease\", section on 'Development of metabolic acidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, in occasional patients with metabolic acidosis and hypokalemia due, for example, to persistent severe diarrhea, the urine pH is above 5.5 despite an appropriate renal acid excretory response [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11558/abstract/1\">",
"     1",
"    </a>",
"    ]. Both the metabolic acidosis and hypokalemia (at least in part by inducing a transcellular cation exchange in which potassium exits the cell in exchange for hydrogen entry into the cell) combine to stimulate both renal ammoniagenesis and secretion of ammonia into the urine. Increased secretion of ammonia may be explained in part by increased synthesis and apical membrane targeting of ammonia transporters in the collecting duct in response to metabolic acidosis and potassium depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11558/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The ammonia in the renal tubule binds to hydrogen ions to form NH4 by the following equation:",
"   </p>",
"   <p>",
"    NH3 &nbsp;+ &nbsp;H &nbsp; &harr; &nbsp; NH4",
"   </p>",
"   <p>",
"    Because of buffering by the high urine concentrations of NH4, the urine hydrogen ion concentration is reduced, and the urine pH is raised and may be above 5.5. This relatively high urine pH in a patient with hyperchloremic, hypokalemic metabolic acidosis may incorrectly suggest that the patient has renal tubular acidosis (RTA) rather than diarrhea. The correct diagnosis of diarrhea-induced metabolic acidosis can be made both from the history (if available and accurate) and the finding of an appropriately negative value for the UAG, reflecting the high urine NH4Cl concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11558/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Limitations of the UAG",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several conditions that disrupt the relationship between the urine NH4 concentration and the UAG. When they occur, the UAG may be misleading and not accurately indicate the etiology of the metabolic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11558/abstract/1,2,12,13\">",
"     1,2,12,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased urinary excretion of unmeasured anions (non-chloride anions) that are not normally present in the urine in high concentrations will disrupt the relationship between the urine NH4 and UAG. Examples of unmeasured urinary anions include beta-hydroxybutyrate and acetoacetate in ketoacidosis, hippurate following toluene inhalation (glue-sniffing), bicarbonate when proximal renal tubular acidosis is treated with alkali therapy, D-lactate in D-lactic acidosis, and 5-oxoproline associated with chronic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ingestion (especially in malnourished women). These anions may be excreted with sodium or potassium or with NH4. The excretion of NH4 with such unmeasured anions will not reduce the UAG as occurs when NH4 is excreted with chloride. In addition, the excretion of sodium or potassium with unmeasured anions contributes to a positive UAG. Thus, the excretion of NH4 together with such anions will not generate a negative UAG. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=see_link\">",
"       \"The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neonates excrete other unmeasured anions at relatively high rates; therefore, the UAG is an unreliable marker of urine NH4 concentration in these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11558/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These conditions in which interpretation of the UAG is limited are relatively frequent causes of metabolic acidosis. Thus, the UAG may commonly be misleading. The urine osmolal gap is another indirect assessment of the urine NH4 concentration that has been proposed and which may perform better under many of these conditions. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     URINE OSMOLAL GAP",
"    </span>",
"    &nbsp;&mdash;&nbsp;When urinary ammonium (NH4) is excreted with an anion other than chloride, such as beta-hydroxybutyrate, acetoacetate, bicarbonate, or hippurate, the urine anion gap (UAG) will not refect the urine NH4 concentration. In such settings, the urine osmolal gap (UOG) is a better indirect surrogate of the urine NH4 concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11558/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. This calculation compares the directly measured urine osmolality to an estimate of the urine osmolality derived from the urine concentrations of sodium, potassium, urea nitrogen (or urea), and, if the dipstick is glucose positive, glucose concentrations, using the [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11558/abstract/9\">",
"     9",
"    </a>",
"    ]following formula:",
"   </p>",
"   <p>",
"    Calculated urine osmolality",
"    <span class=\"nowrap\">",
"     (mosmol/kg)",
"    </span>",
"    &nbsp;= &nbsp;(2 &nbsp;x &nbsp;[Na + K]) &nbsp;+ &nbsp;[urea nitrogen in",
"    <span class=\"nowrap\">",
"     mg/dL]/2.8",
"    </span>",
"    &nbsp;+ &nbsp;[glucose in",
"    <span class=\"nowrap\">",
"     mg/dL]/18",
"    </span>",
"   </p>",
"   <p>",
"    The sodium and potassium concentrations are multiplied by 2 to include the osmotic contributions of their accompanying anions, while the divisors 2.8 and 18 are required to convert the urea nitrogen and glucose concentration units from",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    However, if the urea nitrogen and glucose concentrations are reported in standard units (ie,",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    the following formula should be used:",
"   </p>",
"   <p>",
"    Calculated urine osmolality",
"    <span class=\"nowrap\">",
"     (mosmol/kg)",
"    </span>",
"    &nbsp;= &nbsp;(2 &nbsp;x &nbsp;[Na + K]) &nbsp;+ &nbsp;[urea] &nbsp;+ &nbsp;[glucose]",
"   </p>",
"   <p>",
"    The UOG is the difference between the directly measured and the calculated urine osmolality. Ammonium salts are generally the only other major urinary solutes that contribute importantly to the urine osmolality. Ammonium salts include NH4Cl as well as NH4 excreted with other unmeasured anions such as beta-hydroxybutyrate or hippurate. Thus, the UOG, in contrast to the urine anion gap, is not invalidated by increased excretion of unmeasured anions.",
"   </p>",
"   <p>",
"    The normal value of the UOG is approximately 10 to 100",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11558/abstract/8,9,14,15\">",
"     8,9,14,15",
"    </a>",
"    ]. Ammonium excretion should be approximately one-half of this value (due to accompanying anions) or 5 to 50",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    However, as with the UAG, it is probably best to use the UOG as a qualitative rather than quantitative assessment of the urine NH4 concentration.",
"   </p>",
"   <p>",
"    The major renal response to metabolic acidosis is increased NH4 excretion, and this may exceed 200 to 300",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    with severe metabolic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11558/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Conversely, a value below 75",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (UOG of about 150",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    in a patient with metabolic acidosis indicates an impairment in ammonium excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11558/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the UOG is less than 150",
"      <span class=\"nowrap\">",
"       mosmol/kg",
"      </span>",
"      in a patient with metabolic acidosis, it is likely that NH4 excretion is impaired [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11558/abstract/8,9\">",
"       8,9",
"      </a>",
"      ], as with a distal renal tubular acidosis (RTA).",
"     </li>",
"     <li>",
"      When the UOG exceeds 400",
"      <span class=\"nowrap\">",
"       mosmol/kg,",
"      </span>",
"      it is likely that the urine NH4 concentration is 200",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      or greater [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11558/abstract/9\">",
"       9",
"      </a>",
"      ], as with diarrhea-induced metabolic acidosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The metabolic acidosis generated by toluene inhalation is a good example of a condition in which the UOG is particularly helpful and the UAG may be misleading [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11558/abstract/12\">",
"     12",
"    </a>",
"    ]. Toluene is metabolized to hippuric acid and benzoic acid. To the extent that hippurate and benzoate are retained in the extracellular fluid, a high serum anion gap metabolic acidosis will develop. However, with normal or near-normal renal function, hippurate is rapidly excreted in the urine by both glomerular filtration and tubular secretion. The hippurate anion is initially excreted with sodium and potassium (in this phase, the UOG will be normal and the UAG will become more positive). With time, NH4 excretion progressively increases and, in large part, is excreted as ammonium hippurate. The UAG will remain positive in this setting, erroneously suggesting an impairment in NH4 excretion since the UAG only detects NH4 excreted with Cl. However, the UOG will progressively increase reflecting the NH4 excretion with hippurate.",
"   </p>",
"   <p>",
"    In addition, hypokalemia may result due to enhanced potassium excretion with hippurate. Hypokalemia further increases renal ammoniagenesis. As a result, more hydrogen ions become bound to NH3 to form NH4, and the urine pH can rise to 5.5 or higher. This finding in patients who have a hyperchloremic, hypokalemic metabolic acidosis suggests a distal RTA. However, a large UOG will reveal that NH4 excretion is elevated, helping to exclude a diagnosis of distal RTA. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Limitations of the UAG'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=see_link&amp;anchor=H8#H8\">",
"     \"The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis\", section on 'Toluene inhalation'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H193592503\">",
"     'Uses of the urine anion gap'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The UOG should, under most conditions, be a superior surrogate of urinary NH4 excretion. However, it requires additional urine measurements (four or five versus three measurements when using the UAG) and therefore is more cumbersome and subject to more variability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106019860\">",
"    <span class=\"h2\">",
"     Limitations of the UOG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UOG may fail as an indicator of renal NH4 excretion in certain circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The urinary excretion of osmotically active, non-ammonium solutes that are not included in the above formulas (eg, alcohols [ethanol, methanol, ethylene glycol] and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Urinary tract infections caused by bacteria that produce urease. Urease catalyzes the formation of NH4 and bicarbonate from urea and water. The UOG will increase, reflecting the high NH4HCO3 concentration. However, this NH4 is formed outside the kidney (in the bladder or the collection container) and therefore does not represent renal acid excretion.",
"     </li>",
"     <li>",
"      When large quantities of an intact (undissociated) acid are excreted. This may occur with beta-hydroxybutyric acid in ketoacidosis. In this setting, a component of the osmolal gap may be due to beta-hydroxybutyric acid rather than ammonium. However, this error will be small since beta-hydroxybutyric acid is excreted primarily as the ketoacid anion (and therefore accompanied by sodium, potassium, or ammonium) due to its relatively low pKa (4.7). In patients with diabetic ketoacidosis, the concentration of undissociated beta-hydroxybutyric acid was less than 4",
"      <span class=\"nowrap\">",
"       mmol/L,",
"      </span>",
"      while the concentration of ketoacid anions was more than six times higher [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11558/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15393963\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of the urine anion gap (UAG) and urine osmolal gap (UOG) may be helpful in the evaluation of patients with a normal anion gap (hyperchloremic) metabolic acidosis by providing an estimate of urinary ammonium (NH4) excretion. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The difference between the urine Na + K and urine Cl concentrations has been called the UAG, the urine net charge, or the urine cation gap (all represent the same calculation) (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Urine anion gap'",
"      </a>",
"      above):",
"      <br/>",
"      <br/>",
"      &nbsp; &nbsp; UAG (in",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      &nbsp;= &nbsp;Urine (Na &nbsp;+ &nbsp;K &nbsp;- &nbsp;Cl)",
"     </li>",
"     <li>",
"      The UAG has a positive value (between 20 and 90",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      in healthy individuals. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Urine anion gap'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with normal anion gap (hyperchloremic) metabolic acidosis, the UAG is an indirect estimate of urinary NH4 excretion. Because NH4 is usually excreted with chloride (as NH4Cl), increased NH4 excretion usually increases urine chloride above sodium plus potassium. This results in a",
"      <strong>",
"       negative",
"      </strong>",
"      UAG. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Urine anion gap'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A positive UAG is consistent with low or normal NH4 excretion. As an example, patients who have metabolic acidosis associated with impaired NH4 excretion (such as a distal renal tubular acidosis) will have a positive UAG. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Urine anion gap'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A negative UAG is consistent with increased NH4 excretion (ie, greater than 80",
"      <span class=\"nowrap\">",
"       meq/L).",
"      </span>",
"      As an example, the UAG generally falls to a range between -20 and -50",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in patients who develop metabolic acidosis as a result of diarrhea. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Urine anion gap'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In some cases of diarrhea-induced hyperchloremic metabolic acidosis, especially when hypokalemia also develops, the urine pH may be high (above 5.5), erroneously suggesting a renal tubular acidosis. In these patients, a negative UAG correctly points to diarrhea as the etiology of the acidosis rather than impaired urinary acidification. (See",
"      <a class=\"local\" href=\"#H193592503\">",
"       'Uses of the urine anion gap'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The UAG may be an inaccurate index of urine ammonium concentration when increased urinary excretion of unmeasured anions such as ketoacids, 5-oxoproline, bicarbonate, or hippurate occur. In these settings, the UOG should be used to estimate NH4 excretion. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Limitations of the UAG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The UOG is equal to the measured urine osmolality minus the calculated urine osmolality. The equation for the calculated urine osmolality is (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Urine osmolal gap'",
"      </a>",
"      above):",
"      <br/>",
"      <br/>",
"      Calculated urine osmolality",
"      <span class=\"nowrap\">",
"       (mosmol/kg)",
"      </span>",
"      &nbsp;= &nbsp;(2 &nbsp;x &nbsp;[Na + K]) &nbsp;+ &nbsp;[urea nitrogen in",
"      <span class=\"nowrap\">",
"       mg/dL]/2.8",
"      </span>",
"      &nbsp;+ &nbsp;[glucose in",
"      <span class=\"nowrap\">",
"       mg/dL]/18",
"       <br/>",
"       <br/>",
"       or,",
"      </span>",
"      if standard units",
"      <span class=\"nowrap\">",
"       (mmol/L)",
"      </span>",
"      are used:",
"      <br/>",
"      <br/>",
"      Calculated urine osmolality",
"      <span class=\"nowrap\">",
"       (mosmol/kg)",
"      </span>",
"      &nbsp;= &nbsp;(2 &nbsp;x &nbsp;[Na + K]) &nbsp;+ &nbsp;[urea] &nbsp;+ &nbsp;[glucose]",
"     </li>",
"     <li>",
"      The UOG usually represents NH4 salts. The normal value is 10 to 100",
"      <span class=\"nowrap\">",
"       mosmol/kg;",
"      </span>",
"      NH4 excretion should be approximately one-half this value (due to accompanying anions) or 5 to 50",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      The UOG, in contrast to the UAG, is",
"      <strong>",
"       not",
"      </strong>",
"      invalidated by increased urinary excretion of unmeasured anions. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Urine osmolal gap'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the UOG is less than 150",
"      <span class=\"nowrap\">",
"       mosmol/kg",
"      </span>",
"      in a patient with metabolic acidosis, it is likely that NH4 excretion is impaired, as with a distal renal tubular acidosis (RTA).",
"     </li>",
"     <li>",
"      When the UOG exceeds 400",
"      <span class=\"nowrap\">",
"       mosmol/kg,",
"      </span>",
"      it is likely that the urine NH4 concentration is 200",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      or greater, as with diarrhea-induced metabolic acidosis.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11558/abstract/1\">",
"      Batlle DC, Hizon M, Cohen E, et al. The use of the urinary anion gap in the diagnosis of hyperchloremic metabolic acidosis. N Engl J Med 1988; 318:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11558/abstract/2\">",
"      Halperin ML, Vasuvattakul S, Bayoumi A. A modified classification of metabolic acidosis: a pathophysiologic approach. Nephron 1992; 60:129.",
"     </a>",
"    </li>",
"    <li>",
"     Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.590.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11558/abstract/4\">",
"      Inase N, Ozawa K, Sasaki S, Marumo F. Is the urine anion gap a reliable index of urine ammonium excretion in most situations? Nephron 1990; 54:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11558/abstract/5\">",
"      Oh M, Carroll HJ. Value and determinants of urine anion gap. Nephron 2002; 90:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11558/abstract/6\">",
"      Owen OE, Licht JH, Sapir DG. Renal function and effects of partial rehydration during diabetic ketoacidosis. Diabetes 1981; 30:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11558/abstract/7\">",
"      CLARKE E, EVANS BM, MACINTYRE I, MILNE MD. Acidosis in experimental electrolyte depletion. Clin Sci (Lond) 1955; 14:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11558/abstract/8\">",
"      Kim GH, Han JS, Kim YS, et al. Evaluation of urine acidification by urine anion gap and urine osmolal gap in chronic metabolic acidosis. Am J Kidney Dis 1996; 27:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11558/abstract/9\">",
"      Dyck RF, Asthana S, Kalra J, et al. A modification of the urine osmolal gap: an improved method for estimating urine ammonium. Am J Nephrol 1990; 10:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11558/abstract/10\">",
"      Tizianello A, Garibotto G, Robaudo C, et al. Renal ammoniagenesis in humans with chronic potassium depletion. Kidney Int 1991; 40:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11558/abstract/11\">",
"      Han KH, Lee HW, Handlogten ME, et al. Effect of hypokalemia on renal expression of the ammonia transporter family members, Rh B Glycoprotein and Rh C Glycoprotein, in the rat kidney. Am J Physiol Renal Physiol 2011; 301:F823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11558/abstract/12\">",
"      Carlisle EJ, Donnelly SM, Vasuvattakul S, et al. Glue-sniffing and distal renal tubular acidosis: sticking to the facts. J Am Soc Nephrol 1991; 1:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11558/abstract/13\">",
"      Sulyok E, Guignard JP. Relationship of urinary anion gap to urinary ammonium excretion in the neonate. Biol Neonate 1990; 57:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11558/abstract/14\">",
"      Kamel KS, Halperin ML. An improved approach to the patient with metabolic acidosis: a need for four amendments. J Nephrol 2006; 19 Suppl 9:S76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11558/abstract/15\">",
"      Meregalli P, L&uuml;thy C, Oetliker OH, Bianchetti MG. Modified urine osmolal gap: an accurate method for estimating the urinary ammonium concentration? Nephron 1995; 69:98.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2348 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-B6CE745EC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_18_11558=[""].join("\n");
var outline_f11_18_11558=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15393963\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H529595797\">",
"      BRIEF OVERVIEW OF RENAL ACID EXCRETION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      URINE ANION GAP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H193592503\">",
"      Uses of the urine anion gap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Limitations of the UAG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      URINE OSMOLAL GAP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106019860\">",
"      Limitations of the UOG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15393963\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2348\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2348|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/0/38924\" title=\"table 1\">",
"      Causes of metabolic acidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12762?source=related_link\">",
"      Chapter 11A: Renal hydrogen excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=related_link\">",
"      Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41353?source=related_link\">",
"      Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41430?source=related_link\">",
"      Serum osmolal gap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=related_link\">",
"      The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_18_11559="Care of the uncircumcised penis";
var content_f11_18_11559=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Care of the uncircumcised penis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/18/11559/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/18/11559/contributors\">",
"     Jason M Wilson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/18/11559/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/18/11559/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/18/11559/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/18/11559/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/18/11559/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/18/11559/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 9, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H9377158\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most parts of the world, male circumcision, the elective surgical removal of the skin covering the end of the penis (ie, prepuce or foreskin), is uncommon.",
"   </p>",
"   <p>",
"    The care and complications of the uncircumcised penis will be reviewed here. The procedures, risks, benefits, and complications of circumcision are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/57/15256?source=see_link\">",
"     \"Techniques for neonatal circumcision\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41705?source=see_link\">",
"     \"Neonatal circumcision: Risks and benefits\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4903?source=see_link\">",
"     \"Complications of circumcision\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29532338\">",
"    <span class=\"h1\">",
"     NORMAL DEVELOPMENT OF THE FORESKIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The foreskin is the redundant skin that typically extends about 1 cm beyond the glans (",
"    <a class=\"graphic graphic_picture graphicRef57953 \" href=\"UTD.htm?24/1/24607\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76391 \" href=\"UTD.htm?19/0/19462\">",
"     figure 1",
"    </a>",
"    ). It provides protection to the urethral meatus and glans penis.",
"   </p>",
"   <p>",
"    The normal foreskin begins to develop as an epithelial fold that grows inward from the base of the glans penis at eight to nine weeks gestation with normal completion by 4 to 4.5 months gestation. The squamous epithelial lining of the inner prepuce is contiguous with the glans penis resulting in the normal circumferentially initial adhesions between the inner layer of the prepuce and the glabrous epithelium of the glans penis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86213584\">",
"    <span class=\"h1\">",
"     FORESKIN RETRACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Separation from the foreskin from the glans penis occurs by desquamation and begins late in gestation, but remains incomplete in most male infants at birth. Only about 4 percent of males have a completely retractable foreskin at birth, and in more than half of newborn males, the foreskin cannot be retracted far enough to visualize the urethral meatus [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After birth, penile growth and physiologic erection aid in the desquamation process and the formation of keratinized pearls (smegma) between the layers, which loosens the adhesions and allows retraction of the preputial skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86213710\">",
"    <span class=\"h2\">",
"     Phimosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phimosis is defined as an inability to retract the foreskin (prepuce). The incidence of fully retractable foreskin increases with age as the rate of phimosis decreases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This was illustrated in a study of 2149 Taiwanese school boys, which reported the incidence of the following five categories of preputial anatomy for three different age groups based on grade-level; 1",
"    <sup>",
"     st",
"    </sup>",
"    , 4",
"    <sup>",
"     th",
"    </sup>",
"    , and 7",
"    <sup>",
"     th",
"    </sup>",
"    grade [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fully retractable: 8, 21, and 58 percent, respectively",
"     </li>",
"     <li>",
"      Partial retraction with part of the glans penis visible: 40, 41, and 29 percent, respectively",
"     </li>",
"     <li>",
"      Partial phimosis with only the urethral meatus visible and none of the glans penis: 33, 25, and 7 percent, respectively",
"     </li>",
"     <li>",
"      Phimosis with nonvisualization of the meatus and glans: 17, 10, and 1 percent, respectively",
"     </li>",
"     <li>",
"      Circumcised: 3, 4, and 5 percent, respectively",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Phimosis is divided into physiologic and pathologic forms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physiologic phimosis, which is seen in almost all newborn males, is due to the normal development of congenital adhesions between the foreskin and glans. Physical examination reveals a pliant unscarred preputial orifice [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H172410114\">",
"       'Physiologic phimosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Pathologic phimosis is defined as foreskin that is truly nonretractible secondary to distal scarring of the prepuce, such as occurs with preputial fibrosis due to infection and inflammation. This scarring often appears as a contracted white fibrous ring around the preputial orifice (",
"      <a class=\"graphic graphic_picture graphicRef53082 \" href=\"UTD.htm?43/30/44515\">",
"       picture 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/4\">",
"       4",
"      </a>",
"      ]. The reported incidence of pathologic phimosis ranges from 0 to 16 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/5\">",
"       5",
"      </a>",
"      ]. Differences in cohort age and the definition of pathologic phimosis are responsible for this great rate variability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important for primary care clinicians to be able to distinguish between physiologic and pathologic phimosis so that unnecessary referrals to pediatric urologists can be avoided for the patient and his family. Based on the results of the above study and other reports, it appears that the incidence of pathologic phimosis that requires intervention is very low especially in preadolescent and adolescent males [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/2,6,7\">",
"     2,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9377172\">",
"    <span class=\"h1\">",
"     ROUTINE CARE AND HYGIENE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the circumcision rates decline in both Canada and the United States, it has become increasingly important to educate both parents and care providers on the routine care and hygiene of the uncircumcised male infant [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Optimal education reduces parental anxiety and unnecessary referrals to subspecialists [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/4,10\">",
"     4,10",
"    </a>",
"    ], and, perhaps, lowers the risk of pathologic phimosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence-based guidelines directing preputial care do not exist, but the following approach to routine care is based on expert opinions and observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the newborn and infant, the foreskin requires no special care other than what is provided to the rest of the body. The penis should be washed regularly when a bath is given. Soap can be used provided it is nonirritant and safe for the child&rsquo;s age.",
"     </li>",
"     <li>",
"      Frequent diaper changes to prevent diaper rash and decrease skin irritation.",
"     </li>",
"     <li>",
"      Avoid forcible retraction because tearing may cause bleeding, and can result in fibrosis and the development of pathologic phimosis. Gentle retraction of the foreskin with diaper changes and bathing will allow gradual and progressive retraction of the foreskin over the glans. After six months of age, the foreskin should be gently retracted to its maximal point when washed.",
"     </li>",
"     <li>",
"      As the foreskin naturally begins to retract, cleaning and then drying underneath the foreskin can be performed. After bathing, the retracted foreskin should always be pulled down to its normal position covering the glans penis. Failure to do so may result in paraphimosis (when the foreskin is retracted behind the glans penis and cannot be returned to its normal position), which results in venous and lymphatic congestion of the glans (",
"      <a class=\"graphic graphic_picture graphicRef76100 \" href=\"UTD.htm?22/33/23057\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29302?source=see_link\">",
"       \"Paraphimosis: Definition, pathophysiology, and clinical features\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      As the boy becomes older, he should be instructed on retraction of the foreskin, regular cleaning and drying of the glans, and returning the foreskin to its normal position.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During the newborn examination and well-child visits, assessment should include evaluation of the urinary stream and include the following questions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is the urinary stream strong?",
"     </li>",
"     <li>",
"      Is the urinary stream straight? If the answer is no, is there any dribbling or spraying noted?",
"     </li>",
"     <li>",
"      Does the",
"      <span class=\"nowrap\">",
"       infant/child",
"      </span>",
"      appear comfortable while voiding?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the answer to any of these questions is no, a more in-depth assessment should be performed including, if possible, direct observation of the urinary stream. In some cases, urinary stream abnormalities may be due to complications of the foreskin. (See",
"    <a class=\"local\" href=\"#H172410326\">",
"     'Pathologic conditions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86214250\">",
"    <span class=\"h1\">",
"     ASSOCIATED CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several conditions can be seen in uncircumcised boys; some are benign and only require reassurance to patients and parents, and others are complications that require intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86214258\">",
"    <span class=\"h2\">",
"     Benign conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign conditions that do not usually require intervention but only reassurance include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Physiologic phimosis",
"     </li>",
"     <li>",
"      Preputial cysts due to smegma",
"     </li>",
"     <li>",
"      Transient ballooning of the foreskin",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172410114\">",
"    <span class=\"h3\">",
"     Physiologic phimosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed previously, physiologic phimosis is present in almost all newborn males. Although the spontaneous resolution of physiologic phimosis is high, the rate is variable so it is not possible to set an age by which the foreskin should be normally retractile [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/2,3,9\">",
"     2,3,9",
"    </a>",
"    ]. School-age boys without a fully retractible foreskin and their parents should be counseled that there is normally a wide range of retractibility rate, and over time, there is a very high likelihood physiologic phimosis will spontaneously resolve. The clinician should also reinforce proper preputial hygiene; patients",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parents can be taught to perform gentle stretch exercises [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/10\">",
"     10",
"    </a>",
"    ]. A four- to eight-week course of topical corticosteroids (eg, 0.05 percent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/7/28791?source=see_link\">",
"     betamethasone",
"    </a>",
"    cream) applied directly to the preputial outlet twice daily speeds up the natural process of obtaining foreskin retractility [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/4,5,8,10,11\">",
"     4,5,8,10,11",
"    </a>",
"    ]. However, in our practice, we do not use topical corticosteroids for physiologic phimosis unless it is associated with infections. (See",
"    <a class=\"local\" href=\"#H172410701\">",
"     'Recurrent urinary infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172410292\">",
"    <span class=\"h3\">",
"     Smega and preputial cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desquamated epithelial cells that are trapped under the foreskin are referred to as smega [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/4\">",
"     4",
"    </a>",
"    ]. In boys without a fully retractible foreskin, smega may form white lumps under the foreskin, often referred to as preputial cysts. Preputial cysts are benign and usually are located around the corona. They aid in the process of separation between the foreskin and the glans penis, and are extruded once the foreskin becomes more retractible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172410285\">",
"    <span class=\"h3\">",
"     Foreskin ballooning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient ballooning of the foreskin during voiding is usually benign [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/4\">",
"     4",
"    </a>",
"    ]. However, if urinary retention can only be resolved after applying manual pressure, the parent or care provider should seek medical attention. In all other cases, parents should be assured this is a benign condition that will resolve over time as there is increasing retractibility of the foreskin. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172410326\">",
"    <span class=\"h2\">",
"     Pathologic conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of the foreskin that typically require intervention include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pathologic phimosis",
"     </li>",
"     <li>",
"      Paraphimosis",
"     </li>",
"     <li>",
"      Recurrent urinary tract infections",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Severe/recurrent",
"      </span>",
"      balanoposthitis",
"     </li>",
"     <li>",
"      Balanitis xerotica obliterans",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172410341\">",
"    <span class=\"h3\">",
"     Pathologic phimosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic phimosis is defined as foreskin that is truly nonretractable secondary to distal scarring of the prepuce, such as that which occurs with preputial fibrosis due to trauma, infection,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inflammation. A fibrotic preputial ring (cicatrix) may form from scarring due to forcible retraction or following episodes of balanoposthitis. Cicatrix may also occur from scarring after circumcision. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4903?source=see_link&amp;anchor=H18#H18\">",
"     \"Complications of circumcision\", section on 'Cicatrix'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms of pathologic phimosis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Secondary nonretractability of the foreskin after retractibility at an earlier age",
"     </li>",
"     <li>",
"      Irritation or bleeding from the preputial orifice",
"     </li>",
"     <li>",
"      Dysuria",
"     </li>",
"     <li>",
"      Painful erection",
"     </li>",
"     <li>",
"      Recurrent balanoposthitis",
"     </li>",
"     <li>",
"      Chronic urinary retention with ballooning that is only resolved with manual compression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pathologic phimosis increases the risk of other foreskin complications including paraphimosis, recurrent urinary tract infections,",
"    <span class=\"nowrap\">",
"     recurrent/severe",
"    </span>",
"    balanoposthitis, and balanitis xerotica obliterans.",
"   </p>",
"   <p>",
"    When pathologic phimosis is present, pediatric urologic consultation should be sought. Several options exist for treatment of pathologic phimosis, and families should never be counseled that their child &ldquo;needs&rdquo; a circumcision without considering more conservative interventions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stretching exercises of the prepuce have been reported to have some success in treating pathologic phimosis. In one study that compared stretching and topical corticosteroids to a control group with stretching alone, 60 of 90 children in the control group responded with resolution of phimosis using a protocol of retraction as far back as the appearance of stricture for one minute, performed four times daily for one to three months [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Topical corticosteroids, usually administered concomitantly with routine stretching exercises, are effective in most boys with pathologic phimosis.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/7/28791?source=see_link\">",
"       Betamethasone",
"      </a>",
"      cream (0.05 percent) is the topical agent most frequently used; other agents include 0.01 percent",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/45/40656?source=see_link\">",
"       triamcinolone",
"      </a>",
"      and 0.05 percent",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/63/37872?source=see_link\">",
"       fluticasone",
"      </a>",
"      propionate [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/10-14\">",
"       10-14",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In two case series, the daily application of 0.05 percent betamethasone cream for at least four weeks resulted in complete resolution of phimosis in over 90 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In one study of 137 boys (median age 5.4), the administration of topical corticosteroid applied twice a day, and stretching exercises, which were started five days after the initial application, resulted in a 90 percent rate of retractable foreskin [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/11\">",
"       11",
"      </a>",
"      ]. In this study half of the patients had a phimotic but retractable prepuce, one-third had a nonretractable phimotic ring, and one third had a pinpoint opening. There were no differences in the response rate among the three groups.",
"     </li>",
"     <li>",
"      In another study of 247 boys referred for surgical treatment for phimosis (mean age 7.6 years), the protocol of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/7/28791?source=see_link\">",
"       betamethasone",
"      </a>",
"      cream applied twice a day for 15 days and then once a day for 15 more days, and stretching exercises started seven days after the first application of betamethasone, resulted in a 77 percent resolution rate after one protocol cycle and an additional 20 percent of patients had resolution after a second course [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/10\">",
"       10",
"      </a>",
"      ]. There were no differences in response rate based on the phimosis grade; grade 1: fully nonretractable, grade 2: partial or complete exposure of the glans with a lacerated foreskin, and grade 3: phimotic ring.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alternative surgical procedures to circumcision include preputioplasty (surgical release of the scarred tissue), preputial balloon dilation, and various prepuce preserving plastic surgical procedures designed to widen the preputial ring.",
"     </li>",
"     <li>",
"      Circumcision. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/57/15256?source=see_link\">",
"       \"Techniques for neonatal circumcision\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41705?source=see_link\">",
"       \"Neonatal circumcision: Risks and benefits\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our practice, we initially treat pathologic phimosis with 0.05 percent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/7/28791?source=see_link\">",
"     betamethasone",
"    </a>",
"    cream applied twice a day directly on and around the phimotic ring for eight weeks, and after the fifth day of application, stretching exercises (gentle retraction of the foreskin) performed several times a day. In patients who fail topical corticosteroid therapy, surgical options are presented to the",
"    <span class=\"nowrap\">",
"     patient/family,",
"    </span>",
"    and the choice of intervention is based on the clinical findings and the",
"    <span class=\"nowrap\">",
"     patient/family",
"    </span>",
"    preference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172410653\">",
"    <span class=\"h3\">",
"     Paraphimosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraphimosis is caused by foreskin entrapment behind the coronal sulcus, which may result in venous and lymphatic congestion of the glans, and ultimately arterial compromise (",
"    <a class=\"graphic graphic_picture graphicRef76100 \" href=\"UTD.htm?22/33/23057\">",
"     picture 3",
"    </a>",
"    ). Paraphimosis is a medical emergency and its clinical features and management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29302?source=see_link\">",
"     \"Paraphimosis: Definition, pathophysiology, and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33543?source=see_link\">",
"     \"Paraphimosis reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172410701\">",
"    <span class=\"h3\">",
"     Recurrent urinary infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a four- to eightfold increased risk of urinary tract infection (UTI) in uncircumcised versus circumcised male infants. In boys with recurrent UTI or who have UTI",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    evidence of genitourinary abnormality (eg, renal scarring and vesicoureteral reflux), circumcision may be considered as a potential intervention to decrease the risk of future UTI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172410768\">",
"    <span class=\"h3\">",
"     Balanoposthitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Balanoposthitis is an inflammatory condition of the glans penis and the foreskin (",
"    <a class=\"graphic graphic_picture graphicRef67724 \" href=\"UTD.htm?43/35/44606\">",
"     picture 4",
"    </a>",
"    ). Although the etiology is multifactorial in children, balanoposthitis typically results from poor hygiene that is sometimes complicated by secondary infection. In severe cases, patients may be unable to void, in which case, bladder catheterization is indicated. In patients with urinary obstruction, in whom bladder catheterization is unsuccessful, dorsal slit procedure or incision of a constricting band resulting in phimosis may be required. In patients with recurrent balanoposthitis, pathologic phimosis may be an underlying contributing factor, which should be corrected. (See",
"    <a class=\"local\" href=\"#H172410341\">",
"     'Pathologic phimosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The epidemiology, clinical features, diagnosis, and acute management of balanoposthitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/23/24953?source=see_link\">",
"     \"Balanoposthitis in children: Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33654?source=see_link\">",
"     \"Balanoposthitis in children: Epidemiology and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172410883\">",
"    <span class=\"h3\">",
"     Balanitis xerotica obliterans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Balanitis xerotica obliterans (BXO) is a chronic atrophic dermatitis of unknown etiology. It is the genital analog of lichen sclerosus et atrophicus and is characterized by white atrophic plaques on the glans penis and foreskin. These plaques eventually enlarge and coalesce into a sclerotic mass with resultant adhesions, phimosis, and meatal stenosis. Because it is uncommon in children, BXO disorder is rarely diagnosed by pediatricians (",
"    <a class=\"graphic graphic_picture graphicRef65966 \" href=\"UTD.htm?34/15/35057\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although topical corticosteroids have been used to treat BXO, the results are poor except in mild cases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/15\">",
"     15",
"    </a>",
"    ]. In patients with pathologic phimosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    meatal involvement, circumcision is the preferred intervention as it is curative in most patients. However, if after circumcision BXO is persistent, then meatal reconstruction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a dermatology consult may be necessary.",
"   </p>",
"   <p>",
"    In one case series from Children&rsquo;s Hospital Boston over a ten-year period from 1992 to 2002, none of the 41 patients (mean age 10.6 years) with pathologically confirmed BXO were diagnosed prior to referral [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11559/abstract/16\">",
"     16",
"    </a>",
"    ]. In this cohort of patients, 19 patients underwent curative or repeat circumcision, 11 with BXO involvement of the urethral meatus underwent circumcision with meatotomy or meatoplasty, and 9 patients required extensive plastic surgery, including two who received buccal mucosa grafts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/36/29249?source=see_link\">",
"       \"Patient information: Circumcision in baby boys (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/48/41729?source=see_link\">",
"       \"Patient information: Caring for an uncircumcised penis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/5/1107?source=see_link\">",
"       \"Patient information: Circumcision in baby boys (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172410968\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The foreskin typically extends about 1 cm beyond the glans and provides protection to the urethral meatus and glans penis (",
"      <a class=\"graphic graphic_picture graphicRef57953 \" href=\"UTD.htm?24/1/24607\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef76391 \" href=\"UTD.htm?19/0/19462\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      At birth, almost all male infants do not have a retractable foreskin because of the normal circumferential adhesions between the foreskin and the glans penis. After birth, penile growth and physiologic erection aid in the desquamation process that loosens the adhesions and leads to progressive foreskin retraction. (See",
"      <a class=\"local\" href=\"#H86213584\">",
"       'Foreskin retraction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Phimosis is defined as an inability to retract the foreskin (prepuce) and is divided in two forms. (See",
"      <a class=\"local\" href=\"#H86213710\">",
"       'Phimosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Physiologic due to the normal congenital adhesions between the foreskin and glans seen in almost all normal male newborn infants. This condition normally resolves throughout childhood with an incidence of about 1 percent in 7",
"      <sup>",
"       th",
"      </sup>",
"      grade boys.",
"     </li>",
"     <li>",
"      Pathologic due to scarring of the foreskin leading to a true nonretractible foreskin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend the following routine care of the uncircumcised penis (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9377172\">",
"       'Routine care and hygiene'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The penis should be washed routinely during the normal bathing of any male infant or boy.",
"     </li>",
"     <li>",
"      Avoid forcible retraction. As the foreskin naturally begins to retract, cleaning and then drying underneath the foreskin can be performed. The foreskin should always be pulled down to its normal position covering the glans after drying.",
"     </li>",
"     <li>",
"      In any child who is not toilet-trained, frequent diaper changes to prevent diaper rash and",
"      <span class=\"nowrap\">",
"       foreskin/urethra",
"      </span>",
"      irritation.",
"     </li>",
"     <li>",
"      During routine well-child visits, inclusion of a voiding history to uncover any urinary stream abnormality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign conditions seen in uncircumcised males include physiologic phimosis, preputial cysts due to smegma, and transient ballooning of the foreskin that resolves without manual pressure. Parents should be reassured that these are normal",
"      <span class=\"nowrap\">",
"       variations/findings",
"      </span>",
"      that generally do not need any intervention. (See",
"      <a class=\"local\" href=\"#H86214258\">",
"       'Benign conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications that typically require intervention include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pathologic phimosis increases the risk of other foreskin complications, such as paraphimosis,",
"      <span class=\"nowrap\">",
"       recurrent/severe",
"      </span>",
"      balanoposthitis, and recurrent urinary tract infections. Although several treatment options are available, we suggest initial treatment with a topical corticosteroid (eg, 0.05 percent",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/7/28791?source=see_link\">",
"       betamethasone",
"      </a>",
"      cream twice daily) along with gentle retraction (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Other options include stretch exercises alone and corrective surgery including circumcision. (See",
"      <a class=\"local\" href=\"#H172410341\">",
"       'Pathologic phimosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Paraphimosis, a medical emergency, is caused by foreskin entrapment behind the coronal sulcus, which may result in venous and lymphatic congestion of the glans and ultimately arterial compromise (",
"      <a class=\"graphic graphic_picture graphicRef76100 \" href=\"UTD.htm?22/33/23057\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29302?source=see_link\">",
"       \"Paraphimosis: Definition, pathophysiology, and clinical features\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33543?source=see_link\">",
"       \"Paraphimosis reduction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The risk of recurrent urinary tract infection (UTI) is four- to eightfold greater in uncircumcised versus circumcised male infants. In boys with recurrent UTI, or who have UTI and evidence of genitourinary abnormality (eg, renal scarring and vesicoureteral reflux), circumcision may be considered as a potential intervention to decrease the risk of future UTI.",
"     </li>",
"     <li>",
"      Balanoposthitis, inflammation of the glans penis and the foreskin (",
"      <a class=\"graphic graphic_picture graphicRef67724 \" href=\"UTD.htm?43/35/44606\">",
"       picture 4",
"      </a>",
"      ), typically results from poor hygiene that is sometimes complicated by secondary infection. In severe cases, patients may be unable to void, in which case bladder catheterization is indicated. In patients with urinary obstruction, in whom bladder catheterization is unsuccessful, dorsal slit procedure or incision of a constricting band resulting in phimosis may be required. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/23/24953?source=see_link\">",
"       \"Balanoposthitis in children: Clinical manifestations, diagnosis, and treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33654?source=see_link\">",
"       \"Balanoposthitis in children: Epidemiology and pathogenesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Balanitis xerotica obliterans is a chronic atrophic dermatitis characterized by white atrophic plaques on the glans and prepuce. These plaques eventually enlarge and coalesce into a sclerotic mass with resultant adhesions, pathologic phimosis, and meatal stenosis. In these patients, we suggest circumcision because other treatment options have not been effective (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H172410883\">",
"       'Balanitis xerotica obliterans'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Baskin, LS. Circumcision. In: Handbook of Pediatric Urology, 2nd, Baskin, LS and Kogan BA (Eds), Lippincott Williams and Wilkins, Philadelphia 2005. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11559/abstract/2\">",
"      Hsieh TF, Chang CH, Chang SS. Foreskin development before adolescence in 2149 schoolboys. Int J Urol 2006; 13:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11559/abstract/3\">",
"      Yang C, Liu X, Wei GH. Foreskin development in 10 421 Chinese boys aged 0-18 years. World J Pediatr 2009; 5:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11559/abstract/4\">",
"      McGregor TB, Pike JG, Leonard MP. Pathologic and physiologic phimosis: approach to the phimotic foreskin. Can Fam Physician 2007; 53:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11559/abstract/5\">",
"      Van Howe RS. Cost-effective treatment of phimosis. Pediatrics 1998; 102:E43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11559/abstract/6\">",
"      Shankar KR, Rickwood AM. The incidence of phimosis in boys. BJU Int 1999; 84:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11559/abstract/7\">",
"      GAIRDNER D. The fate of the foreskin, a study of circumcision. Br Med J 1949; 2:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11559/abstract/8\">",
"      Steadman B, Ellsworth P. To circ or not to circ: indications, risks, and alternatives to circumcision in the pediatric population with phimosis. Urol Nurs 2006; 26:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11559/abstract/9\">",
"      Metcalfe PD, Elyas R. Foreskin management: Survey of Canadian pediatric urologists. Can Fam Physician 2010; 56:e290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11559/abstract/10\">",
"      Zampieri N, Corroppolo M, Camoglio FS, et al. Phimosis: stretching methods with or without application of topical steroids? J Pediatr 2005; 147:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11559/abstract/11\">",
"      Orsola A, Caffaratti J, Garat JM. Conservative treatment of phimosis in children using a topical steroid. Urology 2000; 56:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11559/abstract/12\">",
"      Letendre J, Barrieras D, Franc-Guimond J, et al. Topical triamcinolone for persistent phimosis. J Urol 2009; 182:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11559/abstract/13\">",
"      Zavras N, Christianakis E, Mpourikas D, Ereikat K. Conservative treatment of phimosis with fluticasone proprionate 0.05%: a clinical study in 1185 boys. J Pediatr Urol 2009; 5:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11559/abstract/14\">",
"      Palmer LS, Palmer JS. The efficacy of topical betamethasone for treating phimosis: a comparison of two treatment regimens. Urology 2008; 72:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11559/abstract/15\">",
"      Vincent MV, Mackinnon E. The response of clinical balanitis xerotica obliterans to the application of topical steroid-based creams. J Pediatr Surg 2005; 40:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11559/abstract/16\">",
"      Gargollo PC, Kozakewich HP, Bauer SB, et al. Balanitis xerotica obliterans in boys. J Urol 2005; 174:1409.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14539 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-B09A38F648-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_18_11559=[""].join("\n");
var outline_f11_18_11559=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H172410968\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9377158\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29532338\">",
"      NORMAL DEVELOPMENT OF THE FORESKIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86213584\">",
"      FORESKIN RETRACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86213710\">",
"      Phimosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9377172\">",
"      ROUTINE CARE AND HYGIENE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86214250\">",
"      ASSOCIATED CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86214258\">",
"      Benign conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172410114\">",
"      - Physiologic phimosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172410292\">",
"      - Smega and preputial cysts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172410285\">",
"      - Foreskin ballooning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172410326\">",
"      Pathologic conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172410341\">",
"      - Pathologic phimosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172410653\">",
"      - Paraphimosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172410701\">",
"      - Recurrent urinary infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172410768\">",
"      - Balanoposthitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172410883\">",
"      - Balanitis xerotica obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172410968\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/14539\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14539|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/0/19462\" title=\"figure 1\">",
"      Penis anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14539|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/1/24607\" title=\"picture 1\">",
"      Uncircumcised penis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/30/44515\" title=\"picture 2\">",
"      Pathologic phimosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/33/23057\" title=\"picture 3\">",
"      Paraphimosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/35/44606\" title=\"picture 4\">",
"      Balanoposthitis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/15/35057\" title=\"picture 5\">",
"      Balantis xerotica obliterans",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/23/24953?source=related_link\">",
"      Balanoposthitis in children: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33654?source=related_link\">",
"      Balanoposthitis in children: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4903?source=related_link\">",
"      Complications of circumcision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41705?source=related_link\">",
"      Neonatal circumcision: Risks and benefits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33543?source=related_link\">",
"      Paraphimosis reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29302?source=related_link\">",
"      Paraphimosis: Definition, pathophysiology, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/48/41729?source=related_link\">",
"      Patient information: Caring for an uncircumcised penis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/5/1107?source=related_link\">",
"      Patient information: Circumcision in baby boys (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/36/29249?source=related_link\">",
"      Patient information: Circumcision in baby boys (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/57/15256?source=related_link\">",
"      Techniques for neonatal circumcision",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_18_11560="Tests of respiratory muscle strength";
var content_f11_18_11560=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tests of respiratory muscle strength",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/18/11560/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/18/11560/contributors\">",
"     Paul L Enright, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/18/11560/contributors\">",
"     John Moxham, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/18/11560/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/18/11560/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/18/11560/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/18/11560/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/18/11560/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory muscle strength can be assessed by measuring the maximal inspiratory pressure (MIP, PImax, or negative inspiratory force [NIF]) and the maximal expiratory pressure (MEP or PEmax). The MIP reflects the strength of the diaphragm and other inspiratory muscles, while the MEP reflects the strength of the abdominal muscles and other expiratory muscles. Common indications for measurement of the MIP and MEP include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory muscle weakness is suspected, such as a patient with dyspnea, weak cough, and known neuromuscular disease",
"     </li>",
"     <li>",
"      Spirometry detected a pattern of restriction: reduced forced expiratory volume in one second (FEV1), reduced forced vital capacity (FVC), normal",
"      <span class=\"nowrap\">",
"       FEV1/FVC",
"      </span>",
"      ratio, and reduced total lung capacity (TLC) and respiratory muscle weakness is in the differential diagnosis",
"     </li>",
"     <li>",
"      Spirometry detected a low vital capacity (VC) of unknown etiology and respiratory muscle weakness is in the differential diagnosis",
"     </li>",
"     <li>",
"      Spirometry detected a low maximal voluntary ventilation (MVV) maneuver of unknown etiology and respiratory muscle weakness is in the differential diagnosis",
"     </li>",
"     <li>",
"      Evaluation of whether known respiratory muscle weakness has improved, remained stable, or worsened",
"     </li>",
"     <li>",
"      To determine whether there is an increased risk of incident mobility disability in older individuals, hospitalizations and death in patients with COPD, mortality in patients with heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/1-4\">",
"       1-4",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Measurement, interpretation, quality assurance, and clinical applications of the MIP and MEP are discussed in this topic review. Alternative tests of respiratory muscle strength are briefly mentioned. Assessments of other aspects of respiratory function (eg, airflow, lung volumes, gas exchange) are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=see_link\">",
"     \"Diffusing capacity for carbon monoxide\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9141?source=see_link\">",
"     \"Reference values for pulmonary function testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link\">",
"     \"Flow-volume loops\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=see_link\">",
"     \"Office spirometry\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the MIP and MEP requires a mechanical pressure gauge that is connected to a mouthpiece (",
"    <a class=\"graphic graphic_picture graphicRef54650 \" href=\"UTD.htm?3/47/3829\">",
"     picture 1",
"    </a>",
"    ). Electronic devices are also available, which may be hand-held or connected to a computer (",
"    <a class=\"graphic graphic_figure graphicRef81704 \" href=\"UTD.htm?42/8/43137\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The device should contain a small hole (1 mm diameter and 20 to 30 mm in length), which allows an air leak. This prevents the patient from generating pressure by using their cheek muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Maximal inspiratory pressure (MIP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Place a new cardboard mouthpiece or a clean rubber mouthpiece with flanges on the device. Instruct the patient to seal his or her lips firmly around the mouthpiece, exhale slowly and completely, and then \"pull in hard, like you are trying to suck up a thick milkshake.\" Demonstrate the maneuver and have the patient repeat it. The patient should maintain inspiratory pressure for at least 1.5 seconds and the largest negative pressure sustained for at least 1 second (not a transient spike) should be recorded [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/9\">",
"     9",
"    </a>",
"    ]. These durations are estimated by the individual supervising the test. Allow the patient to rest for about one minute and then repeat the maneuver five times. Provide verbal or visual feedback after each maneuver. The goal is for the variability among measurements to be less than 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/10\">",
"     10",
"    </a>",
"    ]. Measurements should be rounded to the nearest 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O.",
"   </p>",
"   <p>",
"    Some patients with orofacial muscle weakness may not be able to obtain a good seal with the lips. It is permissible to allow such patients to use their hand to press their lips against the mouthpiece during each maneuver [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/11\">",
"     11",
"    </a>",
"    ]. Alternatively, the technologist can press the patient's lips against the mouthpiece as necessary to obtain a good seal or a face mask interface can be substituted.",
"   </p>",
"   <p>",
"    Report the maximum value of three maneuvers that varied by less than 20 percent, the variability among measurements, the predicted value, and the lower limit of the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/9\">",
"     9",
"    </a>",
"    ]. Patient cooperation and effort should also be noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Maximal expiratory pressure (MEP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Place a clean mouthpiece on the device. Instruct the patient to inhale completely, push the mouthpiece firmly against his or her lips and teeth, and then \"push (or blow) as hard as possible, like you are trying to fill a very stiff balloon\". Demonstrate the maneuver and have the patient repeat it. The patient should maintain expiratory pressure for at least 1.5 seconds and the largest positive pressure sustained for at least 1 second (not a transient spike) should be recorded [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/9\">",
"     9",
"    </a>",
"    ]. Allow the patient to rest for about one minute and then repeat the maneuver five times. Provide verbal or visual feedback after each maneuver. The goal is for the variability among measurements to be less than 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/10\">",
"     10",
"    </a>",
"    ]. Measurements should be rounded to the nearest 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O.",
"   </p>",
"   <p>",
"    Report the maximum value of three maneuvers that varied by less than 20 percent, the variability among measurements, the predicted value, and the lower limit of the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/9\">",
"     9",
"    </a>",
"    ]. Patient cooperation and effort should also be noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INTERPRETATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Normal versus abnormal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal respiratory muscle strength is identified by comparing the MIP and MEP to a reference range or the lower limit of normal. When lung hyperinflation exists, the MIP should be compared to the expected MIP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Reference range",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reference range is sometimes referred to as the normal range, although the latter term may be misleading because healthy individuals sometimes fall outside the range and individuals with a certain condition occasionally fall within the range.",
"   </p>",
"   <p>",
"    Definitive reference ranges have not been established for the MIP or the MEP. The following reference ranges were extracted from studies of reasonable quality that evaluated individuals in different age ranges (",
"    <a class=\"graphic graphic_table graphicRef52967 \" href=\"UTD.htm?23/62/24556\">",
"     table 1",
"    </a>",
"    ). Taken together, they demonstrate the normal age-related decline of the maximal respiratory pressures (about 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O per decade) and gender differences (about one-third lower in women than men) (",
"    <a class=\"graphic graphic_figure graphicRef70873 \" href=\"UTD.htm?41/57/42909\">",
"     figure 2",
"    </a>",
"    ). Race-specific reference equations for the MIP are unnecessary in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For adults 18 to 65 years old, the reference range for MIP is -92 to -121 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O in men and -68 to -79 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O in women [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/13\">",
"       13",
"      </a>",
"      ]. The mean MEP for men is 140 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O and 95 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O for women.",
"     </li>",
"     <li>",
"      For adults 65 to 85 years old, the reference range for MIP is -65 to -90 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O in men and -45 to -60 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O in women [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/7\">",
"       7",
"      </a>",
"      ]. The reference range for MEP is 140 to 190 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O in men and 90 to 130 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O in women.",
"     </li>",
"     <li>",
"      For children 7 to 13 years old, the reference range for MIP is -77 to -114 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O in boys and -71 to -108 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O in girls [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/14\">",
"       14",
"      </a>",
"      ]. The reference range for MEP is 99 to 161 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O in boys and 74 to 126 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O in girls.",
"     </li>",
"     <li>",
"      For adolescents and young adults 13 to 35 years old, the reference range for MIP is -114 to -121 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O in men and -65 to -85 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O in women [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/15\">",
"       15",
"      </a>",
"      ]. The reference range for MEP is 92 to 95 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O in men and 92 to 95 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O in women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reference equations used to derive these ranges were only able to account for about half of the variability of the measurements; thus, the reference ranges are large compared to those for other pulmonary function measurements (eg, the forced expiratory volume in one second [FEV1]) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Lower limit of normal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lower limit of the normal range (LLN) corresponds to the fifth percentile and is approximately 50 percent of the predicted value [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/7,13\">",
"     7,13",
"    </a>",
"    ]. MIP and MEP values below the LLN are considered abnormal. There is no upper limit of normal for measures of respiratory muscle strength.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Expected MIP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with lung hyperinflation due to severe airway obstruction may generate a low MIP despite normal inspiratory muscle strength [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. This is due to shortening of diaphragmatic muscle fibers and the mechanical disadvantage conferred by lung hyperinflation (",
"    <a class=\"graphic graphic_figure graphicRef70968 \" href=\"UTD.htm?24/21/24926\">",
"     figure 3",
"    </a>",
"    ). In such patients, the MIP should be compared to an expected MIP, instead of the reference range or LLN [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/17\">",
"     17",
"    </a>",
"    ]. The expected MIP is a reference value that is adjusted downward as lung hyperinflation increases (",
"    <a class=\"graphic graphic_figure graphicRef73130 \" href=\"UTD.htm?12/11/12478\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When the MIP is lower than the expected MIP, respiratory muscle weakness should be suspected. An alternative noninvasive test should be performed to confirm inspiratory muscle weakness, since diagnostic accuracy is improved when the results of more than one test are considered [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Test characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Test characteristics of the MIP and MEP have been scarcely studied. It appears that a normal MIP reliably excludes inspiratory muscle weakness (ie, good negative predictive value), but a low MIP does not reliably confirm inspiratory muscle weakness (ie, poor positive predictive value) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/21\">",
"     21",
"    </a>",
"    ]. The poor positive predictive value reflects the high frequency of falsely low MIP measurements due to unrecognized poor effort or technique [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these test characteristics, clinicians must accept the uncertainty that exists when the MIP or MEP is close to the LLN or when the test quality is poor. In such cases, the test can be repeated or an alternative test of respiratory muscle strength can be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/21,23,24\">",
"     21,23,24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Alternative tests'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Detecting change",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detecting a change in respiratory muscle strength can be useful for identifying improvement or progression of the underlying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/25\">",
"     25",
"    </a>",
"    ]. However, true change must be distinguished from normal variation.",
"   </p>",
"   <p>",
"    Studies in healthy individuals demonstrate that 95 percent of normal test-to-test variation has a magnitude less than 25 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Ideally, such a study should be performed by each laboratory using patients with neuromuscular disease. However, in the absence of such data, it is reasonable to use a change of more than 25 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O as the threshold to identify true change of respiratory muscle strength.",
"   </p>",
"   <p>",
"    A true change in respiratory muscle strength should be distinguished from a clinically important change, which has not been reported but is likely to be same or greater. Supporting this view, several studies demonstrated that improvement of the MIP as large as -13 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O and the MEP as large as 24 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O did not correlate with symptomatic improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     QUALITY ASSURANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The validity of the MIP and MEP are directly related to the quality of the test from which they were measured. Potential sources of error that should be considered include patient effort and technique, pressure gauge accuracy, and the patient-device interface.",
"   </p>",
"   <p>",
"    Patient effort and technique are probably the most common causes of error. Several interventions can minimize their impact:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The technologist should act as an enthusiastic and encouraging coach, eliciting maximal effort from the patient for each maneuver.",
"     </li>",
"     <li>",
"      Most clinical laboratories perform only five maneuvers because this is what was done in most studies. However, the best values during a test session are usually obtained after multiple maneuvers (up to 15) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/10,31\">",
"       10,31",
"      </a>",
"      ]. We suggest that up to three additional maneuvers be performed if the last measurement was the highest for the test session, or if the second highest measurement is not at least 90 percent of the highest measurement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevalence of errors due to inaccurate pressure gauges is unknown. However, it is suggested that pressure gauges be verified approximately once a week by delivering 50 and 100 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O of pressure via a water manometer or mercury manometer [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/32\">",
"     32",
"    </a>",
"    ]. The difference between the pressure gauge measurement and the delivered pressure should be less than 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O.",
"   </p>",
"   <p>",
"    Error can also be related to the patient-device interface, particularly when measuring the MEP. To overcome these potential sources of error, the patient-device interface should be assessed during each maneuver. Patients with severe weakness of the facial muscles who are unable to create a seal with a standard mouthpiece may benefit from a face mask interface, having the technologist press their lips against the mouthpiece to obtain a good seal, or an alternative test of respiratory muscle strength. In contrast, patients who do not have respiratory muscle weakness may require a tube interface if the standard mouthpiece or face mask seal is broken during the maneuver. The latter is based on several small observational studies that demonstrated that patients without respiratory muscle weakness frequently broke their seal with a standard mouthpiece or face mask, but not a tube [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We propose that the quality of each test be graded according to patient effort and repeatability (",
"    <a class=\"graphic graphic_table graphicRef72052 \" href=\"UTD.htm?11/59/12219\">",
"     table 2",
"    </a>",
"    ). In this system, excellent effort and repeatability (&lt;5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O difference among measurements) would receive the highest quality grade, while poor maneuvers or poor repeatability (&gt;20 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O difference among measurements) would receive the poorest grade. In general, 80 to 90 percent of healthy adults achieve less than 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O difference among measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/13,35\">",
"     13,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL APPLICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once testing is complete and the MIP and MEP have been determined, they can be applied to the clinical circumstances. The MIP and MEP are rarely used alone; rather, they are considered in conjunction with other measures, most commonly the vital capacity (VC) or the forced vital capacity (FVC). Common settings in which the MIP and MEP are helpful include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diagnosis of respiratory muscle weakness",
"     </li>",
"     <li>",
"      Assessment of the severity of the respiratory muscle weakness, including prediction of clinical sequelae",
"     </li>",
"     <li>",
"      Following the course of the respiratory muscle weakness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of the MIP and MEP in each of these settings is discussed in detail in this section. Pulmonary function testing in the evaluation of respiratory muscle weakness is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link&amp;anchor=H7#H7\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clearly reduced MIP or MEP suggests respiratory muscle weakness, which can have many causes. Possible etiologies include neuromuscular diseases (eg, amyotrophic lateral sclerosis, myasthenia gravis, polymyositis, Guillain-Barr&eacute; syndrome) or systemic conditions that affect skeletal muscle strength (eg, thyrotoxicosis, heart failure, malnutrition, idiopathic myopathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/28,29,36-41\">",
"     28,29,36-41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=see_link\">",
"     \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=see_link\">",
"     \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=see_link\">",
"     \"Clinical manifestations of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Respiratory muscle weakness is also common among patients with chronic obstructive pulmonary disease (COPD), probably due to medications (eg, steroids) and the disease itself [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/42\">",
"     42",
"    </a>",
"    ]. Patients with COPD have an additional reason to have a low MIP that is unrelated to respiratory muscle weakness &ndash; lung hyperinflation. The relative contribution of respiratory muscle weakness and lung hyperinflation to low MIP measurements varies among patients and throughout a patient's disease course [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Expected MIP'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    MIP and MEP measurements can localize respiratory muscle weakness. A low MIP and normal MEP suggests isolated inspiratory muscle weakness (usually diaphragmatic), while a low MIP and MEP suggests generalized skeletal muscle weakness. Isolated expiratory muscle weakness (normal MIP and low MEP) is rare. From a practical standpoint, this differentiation is of minimal diagnostic benefit because many of the causes of respiratory muscle weakness can cause either inspiratory muscle weakness or generalized skeletal muscle weakness.",
"   </p>",
"   <p>",
"    A low-normal or slightly low MIP or MEP can also be due to factors other than respiratory muscle weakness. Such factors include older age, female gender, weak handgrip strength, malnutrition, obesity (&gt;220 pounds, &gt;33 BMI, large waist size, or high percent body fat), poor health, low physical activity, low education, short stature, smoking, and suboptimal technician coaching [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/7,13,35\">",
"     7,13,35",
"    </a>",
"    ]. Pregnancy does not lower the MIP or MEP [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/43\">",
"     43",
"    </a>",
"    ]. In addition, the MIP or MEP can be falsely-low due to problems related to patient effort and technique, pressure gauge accuracy, and the patient-device interface.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MIP and MEP can be used to quantitate the severity of the respiratory muscle weakness and predict its clinical consequences, with lower values indicating more severe weakness and clinical sequelae. This is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduced MIP is associated with increased overall and cardiovascular mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/42,44\">",
"       42,44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A MIP below one-third of normal predicts hypercarbic respiratory failure (PaCO",
"      <sub>",
"       2",
"      </sub>",
"      &gt;45 mmHg) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/36,45\">",
"       36,45",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A MEP less than 60 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O predicts a weak cough with difficulty clearing secretions [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The MIP or MEP is usually already markedly diminished when the symptoms or signs of respiratory muscle weakness emerge. This is due to the large reserve of respiratory muscle strength that normally exists, such that considerable muscle strength must be lost before symptoms or signs develop [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/25\">",
"     25",
"    </a>",
"    ]. This is particularly true for sedentary patients without heart or lung disease. Such patients place minimal demand on their respiratory muscles and, therefore, may not become symptomatic until they have severe respiratory muscle weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial measurements of the MIP and MEP can be used to evaluate whether the respiratory muscle weakness has improved, remained stable, or worsened. This is particularly helpful for evaluating response to therapy (eg, immunosuppressive therapy for myasthenia gravis or Guillain-Barr&eacute; syndrome) and for planning an intervention (eg, mechanical ventilation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link&amp;anchor=H10#H10\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\", section on 'Assess need for ventilatory support'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Comparing measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vital capacity (VC) and the forced vital capacity (FVC) are widely used alternatives to the MIP and MEP that are used to follow the disease course. The difference between the VC and the FVC should be clearly understood. The VC is the maximum volume of gas that can be expelled from full inspiration. The FVC is also the maximum volume of gas that can be expelled from full inspiration, but it is measured when the patient is exhaling with maximal speed and effort. The VC is usually higher than the FVC, with the difference being directly related to the degree of obstruction.",
"   </p>",
"   <p>",
"    Direct comparison of the MIP and FVC demonstrates the following differences:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When measured in the upright position, a decreased FVC is less specific for respiratory muscle strength (it can also be decreased in interstitial lung disease, chest wall disease, and other conditions) and less sensitive for changes in inspiratory muscle strength, compared to the MIP [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/48,49\">",
"       48,49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A fall in the FVC when the patient moves from the upright to the supine position detects inspiratory muscle weakness more reliably than a low MIP [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Comparison of the MIP and VC demonstrates similar sensitivity and specificity for detecting hypercarbic respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/36\">",
"     36",
"    </a>",
"    ]. Specifically, the MIP had a sensitivity and specificity of 55 and 83 percent, respectively, while the VC had a sensitivity and specificity of 53 and 89 percent, respectively.",
"   </p>",
"   <p>",
"    Taken together, the data indicate that no single measure is best for assessing respiratory muscle weakness. In our practice, we make clinical decisions after measuring the MIP, the MEP, and the FVC. We prefer upright and supine FVC measurements to upright FVC measurements alone when the patient is able to perform the maneuver in the supine position. When doubt persists about whether a patient has respiratory muscle weakness, performing another noninvasive diagnostic test, such as the sniff nasal inspiratory pressure (discussed below), improves diagnostic accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Threshold values that may prompt mechanical ventilation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link&amp;anchor=H10#H10\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\", section on 'Assess need for ventilatory support'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ALTERNATIVE TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MIP and MEP are the most common tests of respiratory muscle strength, although alternative methods exist.",
"   </p>",
"   <p>",
"    The sniff nasal inspiratory pressure (SNIP, also known as the sniff nasal inspiratory force [SNIF]) is a noninvasive test of inspiratory strength. Advantages include the simplicity of the maneuver and the absence of a mouthpiece, which is particularly helpful for patients who have facial (ie, bulbar) weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/9\">",
"     9",
"    </a>",
"    ]. The sniff nasal inspiratory pressure is performed by wedging a catheter into one nostril and instructing the patient to sniff through the contralateral unobstructed nostril. The pressure measured in the obstructed nostril is an indicator of respiratory muscle strength.",
"   </p>",
"   <p>",
"    The SNIP correlates strongly with transdiaphragmatic pressure and the MIP in patients who do not have severe airway obstruction; however, it provides no information about expiratory strength [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/9,36,50-52\">",
"     9,36,50-52",
"    </a>",
"    ]. In patients with amyotrophic lateral sclerosis (ALS), a SNIP that is less negative than -40 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O (eg, -20 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O) is associated with nocturnal hypoxemia and an increased risk of death (median survival of six months) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, it predicts six month mortality with a sensitivity of 97 percent and a specificity of 79 percent. In one study, the mean SNIP in Japanese men and women were -77 and -60 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O, respectively, while the LLNs for the SNIP were -33 and -29 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11560/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transdiaphragmatic pressure during inspiration, expiration, a sniff, a cough, or phrenic nerve stimulation is the best measure of respiratory muscle strength. However, the technique is complex, invasive (requires insertion of esophageal and gastric balloon catheters) and performed in only specialized centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory muscle strength can be assessed noninvasively by measuring the maximal inspiratory pressure (MIP, PImax, or negative inspiratory force [NIF]) and the maximal expiratory pressure (MEP or PEmax). The MIP reflects the strength of the diaphragm and other inspiratory muscles, while the MEP reflects the strength of the abdominal muscles and other expiratory muscles. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common indications for measurement of the MIP and MEP include clinically suspected respiratory muscle weakness, spirometry results consistent with respiratory muscle weakness (eg, restrictive pattern, low vital capacity, low maximal voluntary ventilation), and evaluation of whether respiratory muscle weakness has improved, remained stable, or worsened. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The MIP and MEP are measured using the same equipment and using similar techniques. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abnormal respiratory muscle strength is identified by comparing the MIP and MEP to a reference range or the lower limit of normal. When lung hyperinflation exists, the MIP should be compared to the expected MIP. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Normal versus abnormal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A normal MIP reliably excludes inspiratory muscle weakness (ie, good negative predictive value), but a low MIP does not reliably confirm inspiratory muscle weakness (ie, poor positive predictive value), since submaximal patient effort or poor technique are common. When a low MIP is recorded, the measurement of sniff nasal inspiratory pressure (SNIP) is helpful to confirm weakness; it is known that multiple tests increase diagnostic accuracy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Test characteristics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Alternative tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential sources of error that should be considered include patient effort and technique, pressure gauge accuracy, and the patient-device interface. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Quality assurance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once testing is complete and the MIP and MEP have been determined, the measures can be applied to the clinical circumstances. This may include diagnosis of respiratory muscle weakness, determination of its severity, prediction of its clinical sequelae, or evaluation of its clinical course. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical application'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/1\">",
"      Buchman AS, Boyle PA, Leurgans SE, et al. Pulmonary function, muscle strength, and incident mobility disability in elders. Proc Am Thorac Soc 2009; 6:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/2\">",
"      Frankenstein L, Nelles M, Meyer FJ, et al. Validity, prognostic value and optimal cutoff of respiratory muscle strength in patients with chronic heart failure changes with beta-blocker treatment. Eur J Cardiovasc Prev Rehabil 2009; 16:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/3\">",
"      Vilar&oacute; J, Ramirez-Sarmiento A, Mart&iacute;nez-Llorens JM, et al. Global muscle dysfunction as a risk factor of readmission to hospital due to COPD exacerbations. Respir Med 2010; 104:1896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/4\">",
"      Moore AJ, Soler RS, Cetti EJ, et al. Sniff nasal inspiratory pressure versus IC/TLC ratio as predictors of mortality in COPD. Respir Med 2010; 104:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/5\">",
"      Hamneg&aring;rd CH, Wragg S, Kyroussis D, et al. Portable measurement of maximum mouth pressures. Eur Respir J 1994; 7:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/6\">",
"      Watson, L. A method for measuring sniff nasal inspiratory pressure using the PK Morgan Pm meter. Inspire, the Official J Assoc Respir Technicians Physiologists 1997; 1:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/7\">",
"      Enright PL, Kronmal RA, Manolio TA, et al. Respiratory muscle strength in the elderly. Correlates and reference values. Cardiovascular Health Study Research Group. Am J Respir Crit Care Med 1994; 149:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/8\">",
"      Evans JA, Whitelaw WA. The assessment of maximal respiratory mouth pressures in adults. Respir Care 2009; 54:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/9\">",
"      American Thoracic Society/European Respiratory Society. ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med 2002; 166:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/10\">",
"      Wen AS, Woo MS, Keens TG. How many maneuvers are required to measure maximal inspiratory pressure accurately. Chest 1997; 111:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/11\">",
"      Fiz JA, Carreres A, Rosell A, et al. Measurement of maximal expiratory pressure: effect of holding the lips. Thorax 1992; 47:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/12\">",
"      Sachs MC, Enright PL, Hinckley Stukovsky KD, et al. Performance of maximum inspiratory pressure tests and maximum inspiratory pressure reference equations for 4 race/ethnic groups. Respir Care 2009; 54:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/13\">",
"      Harik-Khan RI, Wise RA, Fozard JL. Determinants of maximal inspiratory pressure. The Baltimore Longitudinal Study of Aging. Am J Respir Crit Care Med 1998; 158:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/14\">",
"      Gaultier C, Zinman R. Maximal static pressures in healthy children. Respir Physiol 1983; 51:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/15\">",
"      Leech JA, Ghezzo H, Stevens D, Becklake MR. Respiratory pressures and function in young adults. Am Rev Respir Dis 1983; 128:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/16\">",
"      Polkey MI, Green M, Moxham J. Measurement of respiratory muscle strength. Thorax 1995; 50:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/17\">",
"      Rochester DF. Tests of respiratory muscle function. Clin Chest Med 1988; 9:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/18\">",
"      Orozco-Levi M. Structure and function of the respiratory muscles in patients with COPD: impairment or adaptation? Eur Respir J Suppl 2003; 46:41s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/19\">",
"      Morrison NJ, Richardson J, Dunn L, Pardy RL. Respiratory muscle performance in normal elderly subjects and patients with COPD. Chest 1989; 95:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/20\">",
"      Steier J, Kaul S, Seymour J, et al. The value of multiple tests of respiratory muscle strength. Thorax 2007; 62:975.",
"     </a>",
"    </li>",
"    <li>",
"     Moxham J. Lung function tests: physiological principles and clinical applications. In: Respiratory Muscles, Hughes JB, Pride NB, Saunders WB (Eds), London 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/22\">",
"      Aldrich TK, Spiro P. Maximal inspiratory pressure: does reproducibility indicate full effort? Thorax 1995; 50:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/23\">",
"      Hughes PD, Polkey MI, Kyroussis D, et al. Measurement of sniff nasal and diaphragm twitch mouth pressure in patients. Thorax 1998; 53:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/24\">",
"      Fauroux B, Aubertin G, Cohen E, et al. Sniff nasal inspiratory pressure in children with muscular, chest wall or lung disease. Eur Respir J 2009; 33:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/25\">",
"      Celli BR. Clinical and physiologic evaluation of respiratory muscle function. Clin Chest Med 1989; 10:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/26\">",
"      Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/27\">",
"      Maillard JO, Burdet L, van Melle G, Fitting JW. Reproducibility of twitch mouth pressure, sniff nasal inspiratory pressure, and maximal inspiratory pressure. Eur Respir J 1998; 11:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/28\">",
"      Keenan SP, Alexander D, Road JD, et al. Ventilatory muscle strength and endurance in myasthenia gravis. Eur Respir J 1995; 8:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/29\">",
"      Goswami R, Guleria R, Gupta AK, et al. Prevalence of diaphragmatic muscle weakness and dyspnoea in Graves' disease and their reversibility with carbimazole therapy. Eur J Endocrinol 2002; 147:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/30\">",
"      Nava S, Crotti P, Gurrieri G, et al. Effect of a beta 2-agonist (broxaterol) on respiratory muscle strength and endurance in patients with COPD with irreversible airway obstruction. Chest 1992; 101:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/31\">",
"      Larson JL, Covey MK, Vitalo CA, et al. Maximal inspiratory pressure. Learning effect and test-retest reliability in patients with chronic obstructive pulmonary disease. Chest 1993; 104:448.",
"     </a>",
"    </li>",
"    <li>",
"     American Thoracic Society. Pulmonary Function Laboratory Management and Procedure Manual, Wanger J, Crapo RO, Irvin CG (Eds), 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/33\">",
"      Koulouris N, Mulvey DA, Laroche CM, et al. Comparison of two different mouthpieces for the measurement of Pimax and Pemax in normal and weak subjects. Eur Respir J 1988; 1:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/34\">",
"      Wohlgemuth M, van der Kooi EL, Hendriks JC, et al. Face mask spirometry and respiratory pressures in normal subjects. Eur Respir J 2003; 22:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/35\">",
"      Carpenter MA, Tockman MS, Hutchinson RG, et al. Demographic and anthropometric correlates of maximum inspiratory pressure: The Atherosclerosis Risk in Communities Study. Am J Respir Crit Care Med 1999; 159:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/36\">",
"      Lyall RA, Donaldson N, Polkey MI, et al. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 2001; 124:2000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/37\">",
"      Lechtzin N, Wiener CM, Shade DM, et al. Spirometry in the supine position improves the detection of diaphragmatic weakness in patients with amyotrophic lateral sclerosis. Chest 2002; 121:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/38\">",
"      Polkey MI, Lyall RA, Green M, et al. Expiratory muscle function in amyotrophic lateral sclerosis. Am J Respir Crit Care Med 1998; 158:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/39\">",
"      Teixeira A, Cherin P, Demoule A, et al. Diaphragmatic dysfunction in patients with idiopathic inflammatory myopathies. Neuromuscul Disord 2005; 15:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/40\">",
"      Hughes PD, Polkey MI, Harrus ML, et al. Diaphragm strength in chronic heart failure. Am J Respir Crit Care Med 1999; 160:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/41\">",
"      Ker JA, Schultz CM, Ker J. Respiratory muscle endurance in heart failure--the effect of clinical severity. S Afr Med J 1998; 88 Suppl 1:C20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/42\">",
"      Laghi F, Tobin MJ. Disorders of the respiratory muscles. Am J Respir Crit Care Med 2003; 168:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/43\">",
"      Lemos A, de Souza AI, Figueiroa JN, et al. Respiratory muscle strength in pregnancy. Respir Med 2010; 104:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/44\">",
"      van der Palen J, Rea TD, Manolio TA, et al. Respiratory muscle strength and the risk of incident cardiovascular events. Thorax 2004; 59:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/45\">",
"      Chetta A, Harris ML, Lyall RA, et al. Whistle mouth pressure as test of expiratory muscle strength. Eur Respir J 2001; 17:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/46\">",
"      Man WD, Kyroussis D, Fleming TA, et al. Cough gastric pressure and maximum expiratory mouth pressure in humans. Am J Respir Crit Care Med 2003; 168:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/47\">",
"      Szeinberg A, Tabachnik E, Rashed N, et al. Cough capacity in patients with muscular dystrophy. Chest 1988; 94:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/48\">",
"      Mier A. Respiratory muscle weakness. Respir Med 1990; 84:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/49\">",
"      Jackson CE, Rosenfeld J, Moore DH, et al. A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients. J Neurol Sci 2001; 191:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/50\">",
"      Uldry C, Janssens JP, de Muralt B, Fitting JW. Sniff nasal inspiratory pressure in patients with chronic obstructive pulmonary disease. Eur Respir J 1997; 10:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/51\">",
"      Rafferty GF, Leech S, Knight L, et al. Sniff nasal inspiratory pressure in children. Pediatr Pulmonol 2000; 29:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/52\">",
"      Rieder P, Louis M, Jolliet P, Chevrolet JC. The repeated measurement of vital capacity is a poor predictor of the need for mechanical ventilation in myasthenia gravis. Intensive Care Med 1995; 21:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/53\">",
"      Morgan RK, McNally S, Alexander M, et al. Use of Sniff nasal-inspiratory force to predict survival in amyotrophic lateral sclerosis. Am J Respir Crit Care Med 2005; 171:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11560/abstract/54\">",
"      Kamide N, Ogino M, Yamashina N, Fukuda M. Sniff nasal inspiratory pressure in healthy Japanese subjects: mean values and lower limits of normal. Respiration 2009; 77:58.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6965 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_18_11560=[""].join("\n");
var outline_f11_18_11560=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Maximal inspiratory pressure (MIP)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Maximal expiratory pressure (MEP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INTERPRETATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Normal versus abnormal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Reference range",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Lower limit of normal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Expected MIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Test characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Detecting change",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      QUALITY ASSURANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL APPLICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Comparing measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ALTERNATIVE TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/6965\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6965|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/8/43137\" title=\"figure 1\">",
"      Electronic pressure gauge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/57/42909\" title=\"figure 2\">",
"      Sex-related MIP variation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/21/24926\" title=\"figure 3\">",
"      Muscle length and force",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/11/12478\" title=\"figure 4\">",
"      MIP and lung hyperinflation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6965|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/47/3829\" title=\"picture 1\">",
"      Mechanical pressure gauge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6965|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/62/24556\" title=\"table 1\">",
"      MIP and MEP reference range",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/59/12219\" title=\"table 2\">",
"      Test quality grades",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=related_link\">",
"      Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=related_link\">",
"      Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=related_link\">",
"      Diffusing capacity for carbon monoxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=related_link\">",
"      Flow-volume loops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=related_link\">",
"      Office spirometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9141?source=related_link\">",
"      Reference values for pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=related_link\">",
"      Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_18_11561="Prenatal diagnosis and management of congenital pulmonary airway malformation";
var content_f11_18_11561=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prenatal diagnosis and management of congenital pulmonary airway malformation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/18/11561/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/18/11561/contributors\">",
"     Alexia Egloff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/18/11561/contributors\">",
"     Dorothy I Bulas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/18/11561/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/18/11561/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/18/11561/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/18/11561/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/18/11561/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/18/11561/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5018929\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital lung masses include congenital pulmonary airway malformations (CPAMs), bronchopulmonary sequestration (BPS), and congenital lobar emphysema with bronchial atresia. Hybrid lesions have also been described, suggesting these masses represent a spectrum of abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prenatal diagnosis of these disorders has increased with widespread use of prenatal ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, use of prenatal ultrasound and magnetic resonance (MR) imaging has improved understanding of the natural history of fetal lung lesions. Ultrasound evaluation is sensitive for the diagnosis of many prenatal lung lesions, but has low specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/3\">",
"     3",
"    </a>",
"    ]. Fetal MR imaging improves evaluation of pulmonary anatomy, which can help to confirm or exclude the suspected diagnosis, and provides additional information useful for counseling and obstetrical management [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. A definitive diagnosis is usually not possible without surgical resection and histopathological evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/1,7,8\">",
"     1,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5019038\">",
"    <span class=\"h1\">",
"     IMAGING THE FETAL LUNG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound is the primary modality for imaging the fetal chest and detecting fetal chest masses [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/9\">",
"     9",
"    </a>",
"    ], but MR imaging can be a useful adjunct for confirming the presence of a mass, further characterizing normal and abnormal anatomy, and providing assessment of residual lung volume. Assessment of lung parenchyma sonographically can be limited due to maternal obesity, oligohydramnios, overlying ribs, and fetal lie; MR is less limited by these factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5019063\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;On ultrasound, the normal fetal chest is oval or round, with the heart positioned in the anterior half of the left chest and bordered by lung parenchyma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74495 graphicRef63320 \" href=\"UTD.htm?34/61/35799\">",
"     image 1A-B",
"    </a>",
"    ). Inferiorly, the diaphragms are dome-shaped and hypoechoic. The fetal airway is not well delineated by ultrasound. Lung parenchyma appears homogeneous and slightly hyperechogenic compared to the fetal liver, and its echogenicity increases with gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetal lung volume increases with gestational age with the right lung typically measuring 56 percent of total lung volume. Three-dimensional (3D) and four-dimensional (4D) ultrasound imaging appear to be more useful than two-dimensional ultrasound for estimating lung volume [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5019130\">",
"    <span class=\"h2\">",
"     Magnetic resonance",
"    </span>",
"    &nbsp;&mdash;&nbsp;On MR, the normal fetal lung has a homogeneously moderate high signal on T2w (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74495 \" href=\"UTD.htm?7/54/8035\">",
"     image 1A",
"    </a>",
"    ) chest [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/10\">",
"     10",
"    </a>",
"    ]. The T2 signal increases with increased number of alveoli and production of alveolar fluid and decreases in signal with T1w [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/12\">",
"     12",
"    </a>",
"    ]. When normal lung is compressed by either a lung mass or an extraparenchymal lesion, it appears slightly hypointense compared to noncompressed normal lung [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The liver, mediastinal structures, and lung parenchyma are easily differentiated by MR. Compared to adjacent lung, the liver has a lower signal on T2w and higher signal on T1w. The fetal airway can be seen well due to fluid within the larynx, trachea, and bronchi. The thymus is homogeneous and of higher signal than heart, which appears as a dark flow void. Use of MR for volumetric lung measurements is promising, but investigational.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5019197\">",
"    <span class=\"h1\">",
"     CONGENITAL PULMONARY AIRWAY (CYSTIC ADENOMATOID) MALFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;CPAM, previously known as congenital cystic adenomatoid malformation (CCAM), is one of the most common lung lesions diagnosed prenatally, although the birth prevalence is quite low [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The epidemiology, pathogenesis, and pathology of this lesion, as well as neonatal clinical manifestations, management, and prognosis, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/50/810?source=see_link\">",
"     \"Congenital pulmonary airway (cystic adenomatoid) malformation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CPAM is classified into five types (0, 1, 2, 3, and 4) depending on pathologic characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/15\">",
"     15",
"    </a>",
"    ]. This classification system, although prognostically useful postnatally, is less useful prenatally since tissue is not available for histological analysis. Prenatally, CPAM is classified as macrocystic or microcystic based on ultrasound appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5019266\">",
"    <span class=\"h2\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CPAM is suggested by the presence of macrocysts or a solid-appearing mass in the fetal chest on ultrasound examination. These masses are most commonly identified in the second trimester.",
"   </p>",
"   <p>",
"    In the second trimester, macrocysts (&gt;5 mm) are anechoic and usually surrounded by hyperechogenic lung parenchyma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64147 \" href=\"UTD.htm?15/27/15795\">",
"     image 2",
"    </a>",
"    ). Microcysts (&lt;5 mm) appear as a homogeneous, solid, mass that is hyperechogenic compared to the adjacent normal lung parenchyma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77848 \" href=\"UTD.htm?2/58/2980\">",
"     image 3",
"    </a>",
"    ). Mixed lesions also occur (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71008 \" href=\"UTD.htm?0/51/822\">",
"     image 4",
"    </a>",
"    ). As gestational age increases, microcystic lesions become more difficult to visualize due to increased echogenicity of surrounding normal lung [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/12\">",
"     12",
"    </a>",
"    ]. Shadowing from overlying ribs also makes assessment of the mass more difficult in the third trimester.",
"   </p>",
"   <p>",
"    CPAM has a connection to the tracheobronchial tree; the arterial supply and venous drainage are from the pulmonary circulation, although vascular connections to the systemic circulation have been reported. It affects the right and left lungs with equal frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/1\">",
"     1",
"    </a>",
"    ]; bilateral lung involvement is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/17\">",
"     17",
"    </a>",
"    ]. Only one lobe is involved in 85 to 95 percent of cases and the lower lobe is the most common site, but any lobe can be affected [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/16,18\">",
"     16,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Large lesions can cause mediastinal shift to the contralateral side, possibly with rotation of the heart. The esophagus can become compressed and obstructed, resulting in dilatation of the proximal esophagus, a small stomach, and polyhydramnios. The ipsilateral diaphragm may be flattened. Compression of the inferior vena cava and heart can lead to hydrops fetalis (ie, two or more of the following: pleural effusion, pericardial effusion, skin edema [thickening], ascites, polyhydramnios) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63018 \" href=\"UTD.htm?23/13/23761\">",
"     image 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link\">",
"     \"Nonimmune hydrops fetalis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5019419\">",
"    <span class=\"h2\">",
"     Adjunctive imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;MR imaging is useful for supporting the diagnosis and increasing specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/3,18,19\">",
"     3,18,19",
"    </a>",
"    ]. Macrocysts are high signal on T2w and are usually surrounded by abnormal hyperintense lung parenchyma, while microcystic masses are homogeneously hyperintense on T2w. We suggest fetal MR to better delineate abnormal and normal anatomy when the entire lung is involved by the mass, in the presence of hydrops or bilateral lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/10\">",
"     10",
"    </a>",
"    ], and when the diagnosis is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Color and power Doppler imaging of the pulmonary vasculature can also be helpful in differential diagnosis. (See",
"    <a class=\"local\" href=\"#H5019524\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5019499\">",
"    <span class=\"h2\">",
"     Associated anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ten to 20 percent of patients have associated congenital abnormalities, such as",
"    <strong>",
"    </strong>",
"    esophageal atresia with tracheoesophageal fistula, bilateral renal agenesis or dysgenesis, intestinal atresia, other pulmonary malformations, and diaphragmatic, cardiac, central nervous system, and bony anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/50/810?source=see_link\">",
"     \"Congenital pulmonary airway (cystic adenomatoid) malformation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5019524\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prenatal differential diagnosis of CPAM includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Bronchopulmonary sequestration",
"      </strong>",
"      &mdash; Bronchopulmonary sequestration (BPS) is a homogeneous echogenic mass of the lung parenchyma with well defined borders. In contrast to CPAM, there is no communication with the tracheobronchial tree. BPS has anomalous systemic feeding and draining vessels, which can often be identified by color and power Doppler imaging, whereas blood flow to CPAM is the normal pulmonary vasculature [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/6,23\">",
"       6,23",
"      </a>",
"      ]. Hybrid lesions contain mixed cystic and solid components and anomalous feeding systemic vessels; these lesions have better prognosis than patients with CPAM alone.",
"     </li>",
"     <li>",
"      <strong>",
"       Congenital lobar",
"       <span class=\"nowrap\">",
"        overinflation/congenital",
"       </span>",
"       lobar",
"       <span class=\"nowrap\">",
"        emphysema/bronchial",
"       </span>",
"       atresia &mdash;",
"      </strong>",
"      Criteria for congenital lobar overinflation",
"      <span class=\"nowrap\">",
"       (CLO)/congenital",
"      </span>",
"      lobar emphysema",
"      <span class=\"nowrap\">",
"       (CLE)/bronchial",
"      </span>",
"      atresia include hyperlucent lung, normal lung architecture, and absence of macroscopic cysts. This diagnosis can be difficult to differentiate from microcystic CPAM and BPS prenatally. The presence of normal pulmonary vascularity excludes BPS and the lack of cysts excludes CPAM. Diagnosis is confirmed by postnatal computed tomography [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Bronchogenic cyst &mdash;",
"      </strong>",
"      Bronchogenic macrocysts arise from abnormal budding of the ventral foregut along the tracheobronchial tree. These thin walled cystic lesions are covered by respiratory epithelium [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/14\">",
"       14",
"      </a>",
"      ] and are typically isolated and surrounded by normal lung parenchyma [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/24\">",
"       24",
"      </a>",
"      ]. They can be located in the cervical, paratracheal, subcarinal, hilar or mediastinal area, or within the region of the carina [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/25\">",
"       25",
"      </a>",
"      ]. The diagnosis should be suspected when an isolated macrocyst appears to arise from the wall of the trachea or proximal airways [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/25\">",
"       25",
"      </a>",
"      ]. Fifteen percent of cases are intraparenchymal; in these cases, it may be difficult to differentiate a macrocystic CPAM from a bronchogenic cyst prenatally.",
"     </li>",
"     <li>",
"      <strong>",
"       Diaphragmatic hernia &mdash;",
"      </strong>",
"      Herniated bowel loops in the hemithorax can mimic a multicystic, heterogeneous lung mass. Mediastinal and cardiac deviation may be the only hint that a diaphragmatic hernia (CDH) is present in the occasional cases where the stomach remains infradiaphragmatic. When the stomach is herniated into the hemithorax, nonvisualization of stomach bubble within the abdomen is helpful for making the diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/18,23\">",
"       18,23",
"      </a>",
"      ]. Peristalsis of bowel loops in the thorax can sometimes be seen by ultrasound [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/18\">",
"       18",
"      </a>",
"      ]. Deviation of the umbilical portion of the portal vein suggests liver herniation into the thorax. MR is particularly useful in assessing the amount of liver herniation and delineation of small and large meconium filled bowel in the chest. Meconium is dark on T2 and bright on T1, while liver is high on T2w and intermediate on T2w, thus easily differentiated from adjacent lung. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/50/810?source=see_link\">",
"       \"Congenital pulmonary airway (cystic adenomatoid) malformation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Congenital high airway obstruction &mdash;",
"      </strong>",
"      Congenital high airway obstruction (CHAOS) secondary to laryngeal or tracheal atresia should be included in the differential diagnosis of bilateral large CPAM [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/10,23\">",
"       10,23",
"      </a>",
"      ]. Aberrant pulmonary budding off the foregut is present. Most CHAOS also has a connection with the esophagus. Both lungs appear symmetrically enlarged and echogenic due to fluid trapping. The heart is compressed and the diaphragms flattened and everted. Hydrops can develop. MR demonstrates abnormally large high signal lungs on T2 w. Identification of a fluid filled trachea and bronchi confirms the diagnosis. The prognosis is poor [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Neurenteric/enteric",
"       </strong>",
"      </span>",
"      cysts &mdash;",
"      These cysts are formed by failure of separation of the gastrointestinal track from the primitive neural crest. Neurenteric cysts are typically associated with vertebral anomalies and are located in the posterior mediastinum. Enteric or duplication cysts have no communication with the neural track.",
"     </li>",
"     <li>",
"      <strong>",
"       Mediastinal cystic teratoma &mdash;",
"      </strong>",
"      These tumors can be cystic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      solid and are located in the anterior mediastinum. These tumors have increased vascularity, which can be appreciated on Doppler imaging [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Rare fetal neoplasms",
"      </strong>",
"      &mdash; Rare neoplasms such as the pleuropulmonary blastoma (PPB), congenital peribronchial myofibroblastic tumor (CPMT), and the fetal lung interstitial tumor (FLIT) should also be considered in differential diagnosis. These tumors can be cystic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      solid and mimic a CPAM. While the majority of these tumors have been discovered postnatally, each of these tumors has been diagnosed prenatally, as well [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/27-30\">",
"       27-30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5019798\">",
"    <span class=\"h2\">",
"     Prenatal course",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to predict at the time of the initial ultrasound whether lesions will regress or continue to grow and lead to significant problems, including hydrops, need for surgical intervention, or death. The prenatal course depends on the gestational age, size of the mass, amount of mediastinal shift, fetal hemodynamics, and associated anomalies, more than the type of lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/10,14,16\">",
"     10,14,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Longitudinal studies of CPAM have demonstrated that most CPAMs demonstrate rapid progressive growth from about weeks 20 to 26 of gestation, peaking at about 25 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], and then growth plateaus and often regresses [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/33\">",
"     33",
"    </a>",
"    ]. There are no reliable criteria for determining which lesions will continue to grow versus those that will stabilize or regress.",
"   </p>",
"   <p>",
"    About 50 percent of masses persist to delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/34\">",
"     34",
"    </a>",
"    ]. Fifteen percent of these masses decrease in size during the late second and the third trimesters; the majority have a relative decrease in size due to normal fetal thoracic growth, but a few increase in size [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/16,32\">",
"     16,32",
"    </a>",
"    ]. As masses decrease in size, their echogenicity can become similar to that of surrounding normal lung. This is due to both increase in normal lung echogenicity and decrease in echogenicity of the CPAM. On T2 weighted MR the lesions can become of lower signal intensity than normal lung as they regress. Persistent masses are corroborated on postnatal imaging in over 95 percent of cases.",
"   </p>",
"   <p>",
"    The mass appears to resolve before delivery in the other 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/34\">",
"     34",
"    </a>",
"    ]. Among patients with prenatal resolution of ultrasound findings, 60 percent show no abnormality on postnatal imaging. In these cases, the underlying cause for the visualized anomaly may not be CPAM, but a transient bronchial tree obstruction with retention of fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/34\">",
"     34",
"    </a>",
"    ]. The remaining 40 percent of masses with apparent prenatal resolution are still present postnatally; these cases are not recognized prenatally due to the normal increase in lung echogenicity late in pregnancy, which makes differentiating normal from abnormal lungs difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of hydrops, the prognosis is good with reported live birth rates &ge;95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/19,34,35\">",
"     19,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5019961\">",
"    <span class=\"h3\">",
"     Hydrops",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to one-third of fetuses with CPAM develop hydrops due to hemodynamic alterations from vena cava obstruction and cardiac",
"    <span class=\"nowrap\">",
"     displacement/compression",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/16,31\">",
"     16,31",
"    </a>",
"    ]. The risk is highest in fetuses with large lesions, lesions that persist into the third trimester, and microcystic lesions. If hydrops has not developed by about 28 weeks, it is unlikely to develop since CPAM growth plateaus by the end of the second trimester, and the fetal thorax continues to increase [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/31,33\">",
"     31,33",
"    </a>",
"    ]. Hydrops does not occur after growth plateaus.",
"   </p>",
"   <p>",
"    The presence of hydrops is the most important predictor of poor outcome: the risk of perinatal death approaches 100 percent in the absence of intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/9,10,16\">",
"     9,10,16",
"    </a>",
"    ]. Cases of spontaneous resolution of early hydrops (pleural effusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ascites) without intervention have been reported, but these cases are extremely rare [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetuses with hydrops have a higher CPAM volume referenced to the fetal head (known as the CPAM volume ratio, CVR), as compared with nonhydropic fetuses. CVR has been proposed as a possible predictor of hydrops and outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/31\">",
"     31",
"    </a>",
"    ]. It is obtained by calculating the volume of the lung mass using the formula for the volume of an oval and normalizing it by gestational age (to normalize by gestational age, the lung mass volume should be divided by the head circumference [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/31\">",
"     31",
"    </a>",
"    ]): CVR = height x anteroposterior diameter x transverse diameter x 0.52",
"    <span class=\"nowrap\">",
"     (constant)/head",
"    </span>",
"    circumference.",
"   </p>",
"   <p>",
"    Although data are limited to small series, a CVR cut-off of 1.6 at presentation appears to distinguish fetuses who will or will not develop hydrops [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/31\">",
"     31",
"    </a>",
"    ]. In a series of 58 fetuses with CPAM, the rate of subsequent development of hydrops for CVR &le;1.6 and &gt;1.6 was",
"    <span class=\"nowrap\">",
"     7/42",
"    </span>",
"    (17 percent) and",
"    <span class=\"nowrap\">",
"     12/16",
"    </span>",
"    (75 percent), respectively, and survival was",
"    <span class=\"nowrap\">",
"     40/42",
"    </span>",
"    (94 percent) versus",
"    <span class=\"nowrap\">",
"     9/16",
"    </span>",
"    (56 percent) after fetal intervention, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/31\">",
"     31",
"    </a>",
"    ]. The predictive value of CVR was enhanced by excluding fetuses with CVR &le;1.6 and a dominant cyst, because some of these cysts rapidly enlarged from fluid accumulation while solid cysts grew more slowly. When only fetuses with CVR &le;1.6 and no dominant cysts were considered, hydrops developed in only",
"    <span class=\"nowrap\">",
"     1/36",
"    </span>",
"    (2.8 percent).",
"   </p>",
"   <p>",
"    An additional complication of fetal hydrops is the association with maternal mirror syndrome (generalized maternal edema, often with pulmonary involvement, that &ldquo;mirrors&rdquo; the edema of the hydropic fetus and placenta). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link&amp;anchor=H6#H6\">",
"     \"Nonimmune hydrops fetalis\", section on 'Mirror syndrome'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5020104\">",
"    <span class=\"h2\">",
"     Prenatal management",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a lung mass is first identified, thorough assessment of the entire fetus is important to look for additional anomalies. Particular attention should be paid to mediastinal shift since a severe shift can lead to hydrops. The incidence of chromosomal abnormalities is not increased above baseline in fetuses with CPAM alone; this should be considered when weighing the risks and benefits of invasive prenatal testing to determine the fetal karyotype [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/23\">",
"     23",
"    </a>",
"    ]. The risk of chromosomal abnormalities is increased in fetuses with additional anomalies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nonimmune hydrops.",
"   </p>",
"   <p>",
"    Parents need to be counseled about the possible course of the CPAM during pregnancy (increase or decrease in size, potential for hydrops), the potential need for and the options for prenatal intervention, the differential diagnosis of prenatally suspected CPAM, and postnatal issues (clinical manifestations, postnatal evaluation, postnatal management, potential complications, association with malignancy, prognosis of associated anomalies, and range of outcomes). At initial presentation in the early midtrimester, it is difficult to predict what the outcome will be; some couples may choose pregnancy termination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/50/810?source=see_link\">",
"     \"Congenital pulmonary airway (cystic adenomatoid) malformation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients should have serial prenatal follow-up examinations every one to four weeks to assess change in size of the lung mass, change in CVR, and development of polyhydramnios and hydrops [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/16,31\">",
"     16,31",
"    </a>",
"    ]. The frequency depends on the gestational age and CVR. Closer follow-up should be performed in those patients at high risk of developing hydrops (eg, CVR &ge;1.6, age &lt;26 weeks), whereas the interval between studies can be lengthened if the CPAM is very small or growth has plateaued or is regressing, especially after 30 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/36\">",
"     36",
"    </a>",
"    ]. When incipient hydrops is suspected, assessment every two to three days is not unreasonable.",
"   </p>",
"   <p>",
"    The presence of hydrops is a sign for impending fetal demise and an indication for fetal intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/14\">",
"     14",
"    </a>",
"    ]. This recommendation is based on results from small case series showing good survival (&gt;90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/13\">",
"     13",
"    </a>",
"    ]) if hydrops resolves; no randomized trials have compared management approaches. A systematic review found that prenatal drainage or resection improved survival of hydropic fetuses compared to hydropic controls without these interventions (OR 9, 95% CI 3-101) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For fetuses greater than 32 to 34 weeks of age, early delivery with immediate postnatal resection is a reasonable option [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/16\">",
"     16",
"    </a>",
"    ]. Ex utero intrapartum therapy (EXIT) has been used to stabilize fetuses with large lesions expected to have difficulty breathing at delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5020690\">",
"     'Delivery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For gestations between 20 and 32 weeks, several interventions with the goal of improving fetal hemodynamics and preventing lung hypoplasia have been described and appear to improve survival [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/8,40\">",
"     8,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best approach depends on the type of anomaly (macro- versus microcystic). Drainage procedures are used for CPAMS with dominant cysts, while solid masses are treated by resection or ablation. Karyotype analysis is recommended prior to initiating fetal therapy, given the cost and risk of these procedures and the increased risk of chromosomal abnormality in hydropic fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All of the following interventions should be considered investigational. Studies are limited to case reports and small observational series. These patients should be managed by maternal-fetal medicine specialists with experience in invasive fetal procedures. Successful fetal surgery depends on surgical experience; optimal maternal anesthesia, uterine relaxation, hysterotomy, fetal exposure, and intraoperative fetal monitoring; as well as reliable techniques for reapproximation of the fetal membranes and uterine incision. Close postoperative follow-up is critical for early detection and treatment of maternal and fetal complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5020278\">",
"    <span class=\"h3\">",
"     Antenatal corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steroids are the only medical treatment of CPAM. They are used primarily for treatment of microcystic CPAM, since these masses cannot be managed by minimally invasive procedures, but have been used for macrocystic disease, as well. The potential efficacy of this approach was discovered incidentally when resolution of hydrops was noted after a course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    (12 mg intramuscularly, two doses 24 hours apart) given prophylactically in anticipation of premature delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In uncontrolled studies, maternal steroid administration appeared to reverse hydrops and improve outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/13,42-44\">",
"     13,42-44",
"    </a>",
"    ]. In three studies including a total of 31 patients with microcystic disease and mean CVR 2.5 treated with steroids, hydrops was present at steroid administration in 20 patients (65 percent), hydrops resolved in 16 of these 20 patients (80 percent), and 27 of the 31 patients (87 percent) survived [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/13,42,43\">",
"     13,42,43",
"    </a>",
"    ]. Although these results are better than generally reported in historic controls, some studies without administration of steroids have reported resolution of hydrops in 50 percent of fetuses and a 63 percent survival rate [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. It is possible that fetal thoracic growth",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CPAM regression rather than steroids accounted for the resolution of hydrops, particularly in those cases where improvement did not occur for many weeks.",
"   </p>",
"   <p>",
"    In the largest reported series (10 hydropic fetuses), resolution of hydrops was noted in two patients as soon as five and nine days after steroid administration, but took two to five weeks in five cases, 13 weeks in one case, and did not resolve in the remaining two cases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/13\">",
"     13",
"    </a>",
"    ]. If a course of steroids is administered, ultrasound follow-up should be performed weekly to assess the course of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5020395\">",
"    <span class=\"h3\">",
"     Drainage procedures",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Thoracentesis &mdash;",
"      </strong>",
"      For fetuses with large pleural effusions, thoracentesis to prevent pulmonary hypoplasia is possible, but rapid reaccumulation of fluid limits its usefulness. It is used as a temporizing maneuver to provide prognostic information about the possible result from placement of a thoracoamniotic shunt [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/16,19,26,37\">",
"       16,19,26,37",
"      </a>",
"      ]. The fluid should be sent for cell count to exclude an infectious etiology [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Cyst aspiration &mdash;",
"      </strong>",
"      Aspiration to decompress a large macrocyst and reverse the mediastinal shift is an option. Although fluid reaccumulation is common and limits its usefulness, fluid reaccumulation is not inevitable, as some fetuses will improve after one or two aspirations [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Thoracoamniotic shunt &mdash;",
"      </strong>",
"      If the lesion is macrocystic with a dominant cyst and no large solid component, thoracoamniotic shunting is a more definitive in utero procedure than aspiration for cyst decompression. Survival rates of 63 percent",
"      <span class=\"nowrap\">",
"       (26/41)",
"      </span>",
"      have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/26\">",
"       26",
"      </a>",
"      ]. Complications include displacement or malfunction of the catheter, thrombus occlusion of the catheter, fatal fetal hemorrhage, procedure related placenta abruptio placentae, premature rupture of membranes, and preterm labor [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/19\">",
"       19",
"      </a>",
"      ]. There is also a risk of trauma to the fetal chest wall, especially if the procedure is performed before 20 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/26\">",
"       26",
"      </a>",
"      ]. Microcystic CPAM is not amenable to shunting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5020549\">",
"    <span class=\"h3\">",
"     Surgical resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;For solid or mixed",
"    <span class=\"nowrap\">",
"     solid/cystic",
"    </span>",
"    CPAM with a large solid component, in-utero open resection has been successfully performed. Following resection, hydrops resolves over one to two weeks with reversal of the mediastinal shift over three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/26\">",
"     26",
"    </a>",
"    ]. In one study, surgical resection of the tumor (fetal lobectomy) was performed in 13 hydropic fetuses at 21 to 29 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/16\">",
"     16",
"    </a>",
"    ]. Hydrops resolved in eight fetuses (61 percent), with good subsequent in utero lung growth and neonatal survival. There were four intraoperative or postprocedure fetal deaths and one live born a week after the procedure died of pulmonary hypoplasia. A smaller series reported survival in only two of seven fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maternal-fetal surgery requiring hysterotomy appears to be associated with an increased risk of serious pregnancy complications in the index (premature labor, premature rupture of membranes) and subsequent pregnancy (uterine dehiscence or rupture) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5020610\">",
"    <span class=\"h3\">",
"     Laser ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous laser ablation of solid CPAM has been reported in only a few case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/26,45-48\">",
"     26,45-48",
"    </a>",
"    ]. After two sessions one week apart, tumor size decreased. Complete resolution of fetal hydrops was observed in four of seven cases but only two fetuses survived, possibly because the intervention was initiated when the fetus was already preterminal. Failed attempts of treating CPAM complicated with hydrops with laser ablation procedure suggest that earlier markers are needed to determine which patients have a poor prognosis and might benefit from a debulking procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/45\">",
"     45",
"    </a>",
"    ]. Further research is warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5020665\">",
"    <span class=\"h3\">",
"     Sclerotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single study described fetal sclerotherapy in three patients under 26 weeks with CPAM and hydrops, severe mediastinal shift, and polyhydramnios [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/49\">",
"     49",
"    </a>",
"    ]. Sclerotherapy was performed with percutaneous injection of Ethamolin (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40082?source=see_link\">",
"     ethanolamine oleate",
"    </a>",
"    ) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/6/110?source=see_link\">",
"     Polidocanol",
"    </a>",
"    (aethoxysklerol) into the mass under ultrasound guidance using a 22-gauge needle [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/46\">",
"     46",
"    </a>",
"    ]. Resolution of hydrops and of the mass effect was observed in all cases. The patients were delivered at term without complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5020690\">",
"    <span class=\"h2\">",
"     Delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delivery planning should be in conjunction with the pediatric staff (neonatology, pediatric surgery). If the lung mass has resolved or is small with no mediastinal shift or hydrops, CPAM itself is not an indication for early delivery or cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/26,50\">",
"     26,50",
"    </a>",
"    ]. Neonatal respiratory problems would be unlikely. CVR may help predict the risk of neonatal respiratory problems. In one retrospective study of fetal lung lesions, a final CVR &gt;1.0 in nonhydropic fetuses was predictive of respiratory symptoms at birth (sensitivity, specificity, positive and negative predictive values: 75, 98, 75, and 98 percent) and perinatal resection (sensitivity, specificity, positive and negative predictive values: 100, 98, 75, and 100 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For fetuses with large masses that cause mediastinal shift",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hydrops, delivery should be planned for a tertiary care center with an intensive care nursery capable of resuscitation of a neonate with respiratory difficulties, including capability of extracorporeal membrane oxygenation (ECMO), and with pediatric surgeons experienced in care of these infants [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/19,30\">",
"     19,30",
"    </a>",
"    ]. If hydrops develops after 32 weeks of gestation, early delivery is recommended, possibly with the use of EXIT [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/30\">",
"     30",
"    </a>",
"    ]. In EXIT, the fetus is partially delivered and intubated without clamping the umbilical cord. Uteroplacental blood flow and gas exchange are maintained by using inhalational agents to provide uterine relaxation and amnioinfusion to maintain uterine volume. This provides time for resection of the lung mass prior to complete delivery of the infant in rare instances or, more often, cannulation for extracorporeal membrane circulation, thus creating a controlled situation for delayed removal of the CPAM. Overall fetal survival of 90 percent has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11561/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5020767\">",
"    <span class=\"h2\">",
"     Postnatal issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postnatal presentation, neonatal evaluation and care, complications, and management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/50/810?source=see_link\">",
"     \"Congenital pulmonary airway (cystic adenomatoid) malformation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5020792\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of congenital pulmonary airway malformation (CPAM) is suggested by the presence of macrocysts or a solid-appearing mass in the fetal chest on ultrasound examination. (See",
"      <a class=\"local\" href=\"#H5019266\">",
"       'Prenatal diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Color and power Doppler imaging of the pulmonary vasculature can also be helpful in differential diagnosis. Blood supply from the systemic circulation suggests pulmonary sequestration or a hybrid lesion. (See",
"      <a class=\"local\" href=\"#H5019419\">",
"       'Adjunctive imaging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5019524\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnetic resonance (MR) imaging is used to better delineate abnormal and normal anatomy when the entire lung is involved by the mass, in the presence of hydrops or bilateral lesions, and when the diagnosis is uncertain. (See",
"      <a class=\"local\" href=\"#H5019419\">",
"       'Adjunctive imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most CPAMs demonstrate rapid progressive growth from about weeks 20 to 26 of gestation, peaking at about 25 weeks, and then growth plateaus and often regresses. (See",
"      <a class=\"local\" href=\"#H5019798\">",
"       'Prenatal course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of hydrops, the prognosis is good with reported live birth rates &ge;95 percent. Up to one-third of fetuses with CPAM develop hydrops due to hemodynamic alterations from vena cava obstruction and cardiac",
"      <span class=\"nowrap\">",
"       displacement/compression;",
"      </span>",
"      mortality is high in these fetuses. However, if hydrops has not developed by about 28 weeks, it is unlikely to develop since CPAM growth plateaus by the end of the second trimester, and the fetal thorax continues to increase. (See",
"      <a class=\"local\" href=\"#H5019798\">",
"       'Prenatal course'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5019961\">",
"       'Hydrops'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A CPAM volume ratio (CVR) &ge;1.6 predicts the development of hydrops. The frequency depends on underlying factors and is 17 percent in low risk lesions versus 75 percent in high risk lesions (large lesions, lesions that persist into the third trimester, and microcystic lesions). (See",
"      <a class=\"local\" href=\"#H5019961\">",
"       'Hydrops'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnancies should be followed with serial ultrasound examinations to assess change in size of the lung mass, change in CVR, and development of polyhydramnios and hydrops. (See",
"      <a class=\"local\" href=\"#H5020104\">",
"       'Prenatal management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of hydrops is a sign for impending fetal demise and is an indication for fetal intervention. For fetuses over 32 weeks of gestation, we suggest delivery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For gestations between 20 and 32 weeks, the best approach depends on the type of anomaly (macro- versus microcystic). Drainage procedures are used for CPAMS with dominant cysts, while solid masses are treated by resection or ablation. Karyotype analysis is recommended prior to initiating fetal therapy. (See",
"      <a class=\"local\" href=\"#H5020104\">",
"       'Prenatal management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In uncontrolled studies, maternal steroid administration has been associated with reversal of hydrops. However, it is possible that fetal thoracic growth",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      CPAM regression rather than the steroids accounted for resolution of hydrops. As steroids are the only potential medical treatment of microcystic CPAM that has been reported, administration of one course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      is not unreasonable. (See",
"      <a class=\"local\" href=\"#H5020278\">",
"       'Antenatal corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/1\">",
"      Ankermann T, Oppermann HC, Engler S, et al. Congenital masses of the lung, cystic adenomatoid malformation versus congenital lobar emphysema: prenatal diagnosis and implications for postnatal treatment. J Ultrasound Med 2004; 23:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/2\">",
"      Shanmugam G, MacArthur K, Pollock JC. Congenital lung malformations--antenatal and postnatal evaluation and management. Eur J Cardiothorac Surg 2005; 27:45.",
"     </a>",
"    </li>",
"    <li>",
"     Kline-Fath, BM. Is prenatal sonography accurate in identification of Congenital lung lesions? Scientific paper presented at SPR, Boston, MA. April 15, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/4\">",
"      Breysem L, Bosmans H, Dymarkowski S, et al. The value of fast MR imaging as an adjunct to ultrasound in prenatal diagnosis. Eur Radiol 2003; 13:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/5\">",
"      Quinn TM, Hubbard AM, Adzick NS. Prenatal magnetic resonance imaging enhances fetal diagnosis. J Pediatr Surg 1998; 33:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/6\">",
"      Aite L, Zaccara A, Trucchi A, et al. When uncertainty generates more anxiety than severity: the prenatal experience with cystic adenomatoid malformation of the lung. J Perinat Med 2009; 37:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/7\">",
"      Harmath A, Csaba A, Hauzman E, et al. Congenital lung malformations in the second trimester: prenatal ultrasound diagnosis and pathologic findings. J Clin Ultrasound 2007; 35:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/8\">",
"      Lecomte B, Hadden H, Coste K, et al. Hyperechoic congenital lung lesions in a non-selected population: from prenatal detection till perinatal management. Prenat Diagn 2009; 29:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/9\">",
"      Bulas D. Fetal magnetic resonance imaging as a complement to fetal ultrasonography. Ultrasound Q 2007; 23:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/10\">",
"      Hubbard AM, Adzick NS, Crombleholme TM, et al. Congenital chest lesions: diagnosis and characterization with prenatal MR imaging. Radiology 1999; 212:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/11\">",
"      Ruano R, Joubin L, Aubry MC, et al. A nomogram of fetal lung volumes estimated by 3-dimensional ultrasonography using the rotational technique (virtual organ computer-aided analysis). J Ultrasound Med 2006; 25:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/12\">",
"      Levine D, Barnewolt CE, Mehta TS, et al. Fetal thoracic abnormalities: MR imaging. Radiology 2003; 228:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/13\">",
"      Curran PF, Jelin EB, Rand L, et al. Prenatal steroids for microcystic congenital cystic adenomatoid malformations. J Pediatr Surg 2010; 45:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/14\">",
"      Daltro P, Werner H, Gasparetto TD, et al. Congenital chest malformations: a multimodality approach with emphasis on fetal MR imaging. Radiographics 2010; 30:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/15\">",
"      Stocker JT, Madewell JE, Drake RM. Congenital cystic adenomatoid malformation of the lung. Classification and morphologic spectrum. Hum Pathol 1977; 8:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/16\">",
"      Adzick NS, Harrison MR, Crombleholme TM, et al. Fetal lung lesions: management and outcome. Am J Obstet Gynecol 1998; 179:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/17\">",
"      Maas KL, Feldstein VA, Goldstein RB, Filly RA. Sonographic detection of bilateral fetal chest masses: report of three cases. J Ultrasound Med 1997; 16:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/18\">",
"      Azizkhan RG, Crombleholme TM. Congenital cystic lung disease: contemporary antenatal and postnatal management. Pediatr Surg Int 2008; 24:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/19\">",
"      Mann S, Wilson RD, Bebbington MW, et al. Antenatal diagnosis and management of congenital cystic adenomatoid malformation. Semin Fetal Neonatal Med 2007; 12:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/20\">",
"      Zeidan S, Gorincour G, Potier A, et al. Congenital lung malformation: evaluation of prenatal and postnatal radiological findings. Respirology 2009; 14:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/21\">",
"      Schott S, Mackensen-Haen S, Wallwiener M, et al. Cystic adenomatoid malformation of the lung causing hydrops fetalis: case report and review of the literature. Arch Gynecol Obstet 2009; 280:293.",
"     </a>",
"    </li>",
"    <li>",
"     Stocker, T, Dehner, LP. Pediatric Pathology, 2nd ed, Lippincott Williams and Wilkins,  p.473.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/23\">",
"      Bush A, Hogg J, Chitty LS. Cystic lung lesions - prenatal diagnosis and management. Prenat Diagn 2008; 28:604.",
"     </a>",
"    </li>",
"    <li>",
"     Seo, T, Ando, H, Kaneko, K, et al. Two cases of prenatally diagnosed congenital lobar emphysema caused by lobar bronchial atresia. J Pediatr Surg 2006; 41:e17.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/25\">",
"      Kumar AN. Perinatal management of common neonatal thoracic lesions. Indian J Pediatr 2008; 75:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/26\">",
"      Wilson RD. In utero therapy for fetal thoracic abnormalities. Prenat Diagn 2008; 28:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/27\">",
"      Nasr A, Himidan S, Pastor AC, et al. Is congenital cystic adenomatoid malformation a premalignant lesion for pleuropulmonary blastoma? J Pediatr Surg 2010; 45:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/28\">",
"      Mechoulan A, Leclair MD, Yvinec M, et al. [Pleuropulmonary blastoma: a case of early neonatal diagnosis through antenatal scan screening]. Gynecol Obstet Fertil 2007; 35:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/29\">",
"      Dishop MK, McKay EM, Kreiger PA, et al. Fetal lung interstitial tumor (FLIT): A proposed newly recognized lung tumor of infancy to be differentiated from cystic pleuropulmonary blastoma and other developmental pulmonary lesions. Am J Surg Pathol 2010; 34:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/30\">",
"      Adzick NS. Open fetal surgery for life-threatening fetal anomalies. Semin Fetal Neonatal Med 2010; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/31\">",
"      Crombleholme TM, Coleman B, Hedrick H, et al. Cystic adenomatoid malformation volume ratio predicts outcome in prenatally diagnosed cystic adenomatoid malformation of the lung. J Pediatr Surg 2002; 37:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/32\">",
"      Kunisaki SM, Barnewolt CE, Estroff JA, et al. Large fetal congenital cystic adenomatoid malformations: growth trends and patient survival. J Pediatr Surg 2007; 42:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/33\">",
"      Kunisaki SM, Fauza DO, Barnewolt CE, et al. Ex utero intrapartum treatment with placement on extracorporeal membrane oxygenation for fetal thoracic masses. J Pediatr Surg 2007; 42:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/34\">",
"      Cavoretto P, Molina F, Poggi S, et al. Prenatal diagnosis and outcome of echogenic fetal lung lesions. Ultrasound Obstet Gynecol 2008; 32:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/35\">",
"      Raychaudhuri P, Pasupati A, James A, et al. Prospective study of antenatally diagnosed congenital cystic adenomatoid malformations. Pediatr Surg Int 2011; 27:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/36\">",
"      Coleman BG, Adzick NS, Crombleholme TM, et al. Fetal therapy: state of the art. J Ultrasound Med 2002; 21:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/37\">",
"      Knox EM, Kilby MD, Martin WL, Khan KS. In-utero pulmonary drainage in the management of primary hydrothorax and congenital cystic lung lesion: a systematic review. Ultrasound Obstet Gynecol 2006; 28:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/38\">",
"      Liechty KW. Ex-utero intrapartum therapy. Semin Fetal Neonatal Med 2010; 15:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/39\">",
"      Hedrick HL, Flake AW, Crombleholme TM, et al. The ex utero intrapartum therapy procedure for high-risk fetal lung lesions. J Pediatr Surg 2005; 40:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/40\">",
"      Witlox RS, Lopriore E, Oepkes D. Prenatal interventions for fetal lung lesions. Prenat Diagn 2011; 31:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/41\">",
"      Adzick NS. Management of fetal lung lesions. Clin Perinatol 2009; 36:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/42\">",
"      Morris LM, Lim FY, Livingston JC, et al. High-risk fetal congenital pulmonary airway malformations have a variable response to steroids. J Pediatr Surg 2009; 44:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/43\">",
"      Peranteau WH, Wilson RD, Liechty KW, et al. Effect of maternal betamethasone administration on prenatal congenital cystic adenomatoid malformation growth and fetal survival. Fetal Diagn Ther 2007; 22:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/44\">",
"      Loh KC, Jelin E, Hirose S, et al. Microcystic congenital pulmonary airway malformation with hydrops fetalis: steroids vs open fetal resection. J Pediatr Surg 2012; 47:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/45\">",
"      Bruner JP, Jarnagin BK, Reinisch L. Percutaneous laser ablation of fetal congenital cystic adenomatoid malformation: too little, too late? Fetal Diagn Ther 2000; 15:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/46\">",
"      Fortunato S. Intrauterine laser ablation of a fetal cystic adenomatoid malformation with hydrops: the application of minimally invasive surgical techniques to fetal surgery. Am J Obstet Gynecol 1997; 176:S84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/47\">",
"      Ong SS, Chan SY, Ewer AK, et al. Laser ablation of foetal microcystic lung lesion: successful outcome and rationale for its use. Fetal Diagn Ther 2006; 21:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/48\">",
"      Ruano R, da Silva MM, Salustiano EM, et al. Percutaneous laser ablation under ultrasound guidance for fetal hyperechogenic microcystic lung lesions with hydrops: a single center cohort and a literature review. Prenat Diagn 2012; 32:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/49\">",
"      Berm&uacute;dez C, P&eacute;rez-Wulff J, Arcadipane M, et al. Percutaneous fetal sclerotherapy for congenital cystic adenomatoid malformation of the lung. Fetal Diagn Ther 2008; 24:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/50\">",
"      Marshall KW, Blane CE, Teitelbaum DH, van Leeuwen K. Congenital cystic adenomatoid malformation: impact of prenatal diagnosis and changing strategies in the treatment of the asymptomatic patient. AJR Am J Roentgenol 2000; 175:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11561/abstract/51\">",
"      Ehrenberg-Buchner S, Stapf AM, Berman DR, et al. Fetal lung lesions: can we start to breathe easier? Am J Obstet Gynecol 2013; 208:151.e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14207 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4AAF914B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_18_11561=[""].join("\n");
var outline_f11_18_11561=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5020792\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5018929\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5019038\">",
"      IMAGING THE FETAL LUNG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5019063\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5019130\">",
"      Magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5019197\">",
"      CONGENITAL PULMONARY AIRWAY (CYSTIC ADENOMATOID) MALFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5019266\">",
"      Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5019419\">",
"      Adjunctive imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5019499\">",
"      Associated anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5019524\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5019798\">",
"      Prenatal course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5019961\">",
"      - Hydrops",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5020104\">",
"      Prenatal management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5020278\">",
"      - Antenatal corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5020395\">",
"      - Drainage procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5020549\">",
"      - Surgical resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5020610\">",
"      - Laser ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5020665\">",
"      - Sclerotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5020690\">",
"      Delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5020767\">",
"      Postnatal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5020792\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/14207\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/14207|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/54/8035\" title=\"diagnostic image 1A\">",
"      MR normal fetal chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/14/44257\" title=\"diagnostic image 1B\">",
"      Prenatal ultrasound image of a normal fetal chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/27/15795\" title=\"diagnostic image 2\">",
"      Macrocystic type1 CPAM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/58/2980\" title=\"diagnostic image 3\">",
"      Microcystic type3 CPAM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/51/822\" title=\"diagnostic image 4\">",
"      Mixed type2 CPAM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/13/23761\" title=\"diagnostic image 5\">",
"      Hydrops with ascites and pleural effusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/50/810?source=related_link\">",
"      Congenital pulmonary airway (cystic adenomatoid) malformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=related_link\">",
"      Nonimmune hydrops fetalis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_18_11562="Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children";
var content_f11_18_11562=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/18/11562/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/18/11562/contributors\">",
"     Shakila Khan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/18/11562/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/18/11562/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/18/11562/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/18/11562/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/18/11562/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/18/11562/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aplastic anemia can result from either inherited or acquired causes. The incidence is triphasic, with small peaks at two to five years (secondary to inherited disorders) and 20 to 25 years, although the majority of patients present beyond 55 to 60 years of age.",
"   </p>",
"   <p>",
"    The use of hematopoietic cell transplantation in children with idiopathic severe aplastic anemia and Fanconi anemia will be reviewed here. The causes and clinical presentation of acquired and inherited aplastic anemia and the use of hematopoietic cell transplantation in children with Diamond-Blackfan anemia and the myelodysplastic syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=see_link\">",
"     \"Acquired aplastic anemia in children and young adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link\">",
"     \"Inherited aplastic anemia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17030?source=see_link\">",
"     \"Hematopoietic cell transplantation for Diamond-Blackfan anemia and the myelodysplastic syndromes in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term \"hematopoietic cell transplantation\" (HCT) will be used throughout this topic as a general term to cover transplantation of progenitor cells from any source (eg, bone marrow, peripheral blood, cord blood). Otherwise, the source of such cells will be specified (eg, autologous peripheral blood progenitor cell transplantation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IDIOPATHIC SEVERE APLASTIC ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic severe aplastic anemia (SAA) is a rare but serious disorder in children. The criteria for",
"    <strong>",
"     severe",
"    </strong>",
"    aplastic anemia (SAA) are [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A marrow biopsy showing less than 25 percent of normal cellularity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     OR",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A marrow showing less than 50 percent normal cellularity in which fewer than 30 percent of the cells are hematopoietic and at least two of the following are present: absolute reticulocyte count below",
"      <span class=\"nowrap\">",
"       40,000/microL;",
"      </span>",
"      absolute neutrophil count (ANC) less than",
"      <span class=\"nowrap\">",
"       500/microL;",
"      </span>",
"      or platelet count below",
"      <span class=\"nowrap\">",
"       20,000/microL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hematopoietic cell transplantation (HCT) with an HLA-identical sibling currently is the treatment of choice for a child with SAA because it offers a cure by restoration of normal hematopoiesis and is associated with low mortality and morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The results of HCT for SAA, whether from single centers or registries, have shown remarkable improvement over the past 30 years. In Seattle, for example, survival has improved from approximately 45 percent in the 1970s to approximately 90 percent during the late 1980s and 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/4\">",
"     4",
"    </a>",
"    ]. Similarly, survival reported by the European Group for Bone Marrow Transplantation has improved from 43 percent in the 1970s to 72 percent in 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Graft rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;By the mid-1970s, graft rejection was recognized as a frequent complication following HCT for SAA. Rejection is probably caused by allosensitization of the recipient to minor histocompatibility antigens through the transfusion of red cells and platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/6\">",
"     6",
"    </a>",
"    ]. As a result, the recommendation is that transfusions be avoided as much as possible in patients with aplastic anemia who are being considered for HCT. In particular, the patient should not receive blood products from the proposed transplant donor. The addition of antithymocyte globulin (ATG) to the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    preparative regimen has also contributed to the lower risk of graft failure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective analysis from Seattle of a large cohort of patients with SAA, studied over a period of 26 years, showed a decreased incidence of graft rejection from 35 to 9 percent and improved survival from 41 to 90 percent between the early 1970s and the late 1980s and 1990s, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/8\">",
"     8",
"    </a>",
"    ]. It also showed an increase in the proportion of patients who did not require a second transplant for graft rejection from 78 percent to 92 percent in the same time period, coupled with an increase in 10-year probability of survival after second transplant from 5 to 83 percent. Second transplant parameters included in the univariate analysis showed that younger patient age (&lt;18 years) was associated with improved survival, confirming the premise that transplant conditioning regimens are better tolerated by children and young adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10343810\">",
"    <span class=\"h2\">",
"     Outcome following transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall excellent survival and low morbidity render allogeneic transplant the treatment of choice for children and adolescents with SAA. The Seattle study mentioned above noted three factors contributing to this overall improvement in transplant outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduction in the incidence, severity, and mortality from acute graft-versus-host disease (GVHD) through improved GVHD prophylaxis with a combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , instead of single drug therapy with either drug. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=see_link\">",
"       \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A reduction in the incidence of marrow graft rejection as a result of more aggressive treatment regimens, use of immunosuppression, and changes in the quality and quantity of preceding blood transfusion products. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link\">",
"       \"Preparative regimens for hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An increase in survival after second transplants (83 versus 5 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several other studies performed in children have shown similar results with good outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In addition, better outcomes have been reported if patients undergo transplantation early, before significant numbers of transfusions have been given and before the onset of serious infections [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cohort of 17 pediatric patients with SAA reported in 2007, a conditioning regimen of 3 Gy total body irradiation,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      with antithymocyte globulin (for patients with unrelated donors) or without (for patients with related donors) resulted in a survival rate of 82 percent at a median follow-up of 67 months [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Seattle investigators reported on results in 31 children with SAA who received HLA-matched related donor transplants between 1989 and 2010 [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/14\">",
"       14",
"      </a>",
"      ]. These children received a preparative regimen with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and ATG and GVHD prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      . At a median follow-up of 6.1 years, five-year estimated overall survival was 100 percent; estimated probabilities of grades III-IV acute GVHD and two-year estimates of extensive chronic GVHD were 3 and 10 percent, respectively.",
"     </li>",
"     <li>",
"      A retrospective study analyzed the survival of 44 successive children with idiopathic SAA who had received a 10-antigen matched unrelated donor transplant in the UK [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/15\">",
"       15",
"      </a>",
"      ]. Forty of these children had previously failed to respond to immunosuppressive therapy. Transplant conditioning included",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      without radiotherapy. The estimated five-year failure-free survival was 95 percent (95% CI 81-99) with no cases of graft failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Reappearance of recipient-derived cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;In selected cases, serial measurements of chimerism might be performed before and during withdrawal of immunosuppression in order to detect reappearance of recipient cells, which may herald graft rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although this practice may provide important information, there is no generally accepted intervention that has been effective in enhancing donor-specific engraftment. Donor leukocyte infusions have been attempted, but often do not result in enhancement of donor-specific engraftment, and the risk of GVHD is substantial.",
"   </p>",
"   <p>",
"    Other approaches include infusing CD34+ selected donor cells as well as altering the immunosuppressive regimen. At the current time there is no universally accepted practice and additional studies are needed in this area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Graft-versus-host disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The other complication that is a major cause of mortality and morbidity, both as an immediate and a delayed consequence of allogeneic HCT, is graft-versus-host disease (GVHD). GVHD is mediated by donor lymphocytes; histoincompatibility is a major risk factor for GVHD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18826?source=see_link\">",
"     \"Pathogenesis of graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A clear association between age and risk of GVHD independent of the degree of histoincompatibility also exists [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. The increased risk of GVHD with age contributes to poor survival post-transplant in older patients. As an example, for transplants reported to the International Bone Marrow Transplant registry between 1986 and 1992, the total five-year survival rate was 66 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/20\">",
"     20",
"    </a>",
"    ]. However, survival was higher for children younger than 16 years old compared with adults older than 25 years old (75 versus 60 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Alternatives to allogeneic HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unfortunately, the use of allogeneic sibling transplants in children with SAA is limited to a minority of patients, as there is only a 25 to 35 percent probability of finding a fully compatible sibling in the recipient's family.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with SAA who have an HLA-identical sibling donor should receive allogeneic HCT as first treatment, as there is evidence that use of other agents (eg, androgens, immunosuppressive therapy) before attempting HCT compromises overall survival [",
"      <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/3,21,22\">",
"       3,21,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children with SAA who lack an HLA-identical sibling donor need some form of alternative therapy such as immunosuppressive therapy while a HCT donor search is conducted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive therapy is an acceptable alternative for children who do not have a suitable donor. The current treatment of choice is intensive immunosuppression using a combination of ATG,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , with or without the addition of growth factors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/3\">",
"     3",
"    </a>",
"    ]. Another possible approach is the administration of high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (CTX) as used for conditioning for bone marrow transplantation (200",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    given in divided doses over four days) but without the infusion of marrow. In one study, seven of ten patients with SAA treated with this regimen (with or without cyclosporine) achieved a complete response, with six of these patients being alive and in continuous complete remission at 7 to 18 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/23\">",
"     23",
"    </a>",
"    ]. These results need confirmation in a larger number of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=see_link\">",
"     \"Acquired aplastic anemia in children and young adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients without suitable donors (ie, HLA-matched related or HLA-matched unrelated donors) who do not respond to immunosuppressive therapy, and those who have received immunosuppressive therapy before undergoing allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/21\">",
"     21",
"    </a>",
"    ], have poor outcomes; therapeutic choices for such children are limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     HCT from matched unrelated donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplantation from a matched unrelated donor is a potentially curative alternative for patients who lack a related donor and fail immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in a study of Japanese children with severe or very severe AA, 60 of the 205 children (29 percent) failed to respond to immunosuppressive therapy after six months, and were considered for second-line treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/25\">",
"     25",
"    </a>",
"    ]. The estimated five-year failure-free survival of the 31 patients receiving HCT from an alternative donor was 84 percent.",
"   </p>",
"   <p>",
"    A search for a compatible unrelated donor is usually initiated at the time of starting the immunosuppressive therapy to save time if transplantation becomes necessary. Historic trials using partially matched family donors or matched unrelated donors have demonstrated limited success, with multiple treatment-related complications, including high rates of graft rejection and severe GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, results continue to improve such that matched unrelated donor HCT has achieved outcomes similar to those of matched sibling donor HCT; results are particularly favorable in children [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/25,28-32\">",
"     25,28-32",
"    </a>",
"    ]. The improved survival with transplants from unrelated donors is a result of several factors, including advances in HLA typing using molecular techniques (as only approximately 55 percent of donor and recipient pairs that are serologically identical are highly matched by molecular typing) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/33\">",
"     33",
"    </a>",
"    ], better GVHD prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/34,35\">",
"     34,35",
"    </a>",
"    ], and antiviral prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The availability of grafts from matched unrelated donors in the United States is much higher in Caucasians than in certain ethnic minorities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H13#H13\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'Matched unrelated donors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A large, single institutional study in children and young adults with SAA was published by the Medical College of Wisconsin [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/38\">",
"     38",
"    </a>",
"    ]. They used a more immunosuppressive conditioning regimen along with radiation and T-cell depletion in 28 patients, ranging in age from 9 months to 24 years (median 8.5 years). Nine donor-recipient pairs were fully HLA-matched, 13 had a single antigen mismatch, and 6 had 2 or more HLA disparities. Three patients did not engraft and died from infectious and hemorrhagic complications, and ten died of other complications (infection, hepatic veno-occlusive disease, B-cell lymphoproliferative disease, and renal failure). At a follow-up of one to eight years, the overall survival rate was 54 percent. Performance status was &ge;90 percent in all survivors. Of 25 patients who could be evaluated, grades 0, I, II, III, and IV GVHD were noted in 12, 60, 16, 4, and 8 percent, respectively. Of 19 patients evaluated for chronic GVHD, 42 percent had limited and 10 percent had extensive GVHD.",
"   </p>",
"   <p>",
"    In a report from Seattle, which included children and adults, conditioning for transplantation was achieved with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , ATG, and total body irradiation (TBI) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/39\">",
"     39",
"    </a>",
"    ]. In this study, 87 patients ranging in age from 1.3 to 54 years (median, 18.6 years) were treated. The interval from diagnosis to transplant was 3 to 328 months (median, 14.6 months). All patients had been transfused, and all had received immunosuppressive therapy and other modalities. In 62 patients, the donor was fully HLA-matched, whereas the donor differed by one to three alleles in the remaining 25. Pulmonary toxicity was prominent at higher doses of TBI and was less severe in cohorts receiving TBI dose reduction. All but 5 percent of patients engrafted with the use of this regimen. At a median follow-up of 7 years, survival was 61 versus 40 percent for those with or without an HLA-identical transplant, respectively.",
"   </p>",
"   <p>",
"    In a report of 195 patients &lt;20 years of age with SAA who received an NMDP-facilitated unrelated donor HCT between 1989 and 2003 in the United States, the five-year probability of overall survival after an allele-level HLA-A, -B, -C, -DRB1 matched transplant was 57 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/40\">",
"     40",
"    </a>",
"    ]. For those receiving an allele-level HLA-A, -B, -C, -DRB1 mismatched transplant, the five-year overall survival was considerably less, at 39 percent.",
"   </p>",
"   <p>",
"    Two studies evaluated a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    as a conditioning regimen for MUD HCT in patients with aplastic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Grade III-IV GVHD was not seen in either study, and rates of chronic GVHD were zero and 4 percent. Overall survival at two years was 83 percent in one of the studies.",
"   </p>",
"   <p>",
"    The above results for allele-level matched unrelated donor transplantation are encouraging and provide an option for patients with SAA without a related donor who have not received immunosuppressive therapy (IST) or who have failed a first course of IST. Because the reported response rates to a first cycle of IST are in the range of 50 to 60 percent and response rates to a second cycle of IST for patients who did not respond to a first course are in the range of 35 to 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/43-45\">",
"     43-45",
"    </a>",
"    ], it has been suggested that subjects failing a first course of IST receive a second course before considering an unrelated donor HCT for older patients and for those who lack an allele-matched donor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An ongoing study through the Bone Marrow Transplantation Clinical Trials Network (BMT-CTN) is evaluating the preparative regimen for patients undergoing allogeneic HCT from an unrelated donor. In this study, four different doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    are under evaluation along with low dose TBI and ATG. Results from this study may be able to identify the optimal preparative regimen for this patient population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FANCONI ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fanconi anemia (FA) is an autosomal recessive disorder characterized by several congenital anomalies, progressive bone marrow failure, and an increased incidence of malignancies. Cells from patients with FA are hypersensitive to DNA-crosslinking agents, which has been used as a diagnostic tool [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/46\">",
"     46",
"    </a>",
"    ]. Current management consists of supportive modalities, androgens, and hematopoietic growth factors, which can achieve a transient improvement in hematopoietic function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link&amp;anchor=H4#H4\">",
"     \"Inherited aplastic anemia in children\", section on 'Fanconi anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, a large number of responders ultimately become refractory to such treatment or develop intolerable side effects. For such patients, allogeneic HCT is the only treatment option that can restore normal hematopoiesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical indications for HCT in patients with Fanconi anemia are [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe bone marrow failure",
"     </li>",
"     <li>",
"      Myelodysplastic syndrome (MDS)",
"     </li>",
"     <li>",
"      Acute myelogenous leukemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who have an HLA-identical related donor, HCT is generally performed as soon as severe marrow failure develops. Ideally, HCT should be performed before the patient becomes dependent on transfusions, to minimize the risk of graft failure.",
"   </p>",
"   <p>",
"    For patients without an HLA-identical related donor, HCT generally is not recommended until failure of other treatment modalities, including androgens and transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/47\">",
"     47",
"    </a>",
"    ]. This is because of relatively high risks of graft failure and GVHD when matched unrelated donors are used for patients with FA [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Alternative donors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with FA and myelodysplasia or acute myelogenous anemia have a worse prognosis than those with bone marrow failure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/47,49\">",
"     47,49",
"    </a>",
"    ]. These patients may require a pretransplant conditioning regimen that is more intensive than those used for FA patients with bone marrow failure, but less intensive than those used for AML in patients without FA [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hypersensitivity to routine conditioning agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unfortunately, individuals with FA are uniquely hypersensitive to HCT-conditioning agents. Early experience with HCT using matched sibling donors was associated with poor outcomes caused by increased regimen-related toxicity, infectious complications, and high rates of GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cyclophosphamide-containing regimens",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     HLA-identical related donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and thoracoabdominal radiation regimen for patients with FA has resulted in improved outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. Excellent results have been described in FA patients after HCT with HLA-identical siblings using the same or similar conditioning regimens, with single institutions and multicenter studies reporting 70 to 90 percent probability of long term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/56-60\">",
"     56-60",
"    </a>",
"    ], even in patients presenting with myelodysplasia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clonal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (ie, 60 to 80",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    total dose) has also been used in the absence of radiation therapy with excellent results. As an example, 21 of 23 patients given cyclophosphamide at a total dose of 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    had sustained engraftment, with 22 alive at a median follow-up of 16 months [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/62\">",
"     62",
"    </a>",
"    ]. Of interest, the incidence of grade II-III acute GVHD was significantly lower (14 versus 57 percent) for those treated with the lower (ie, 60",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    versus the higher (80",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    dose of cyclophosphamide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Alternative donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unfortunately, the majority of patients with FA do not have a normal HLA-matched sibling to serve as a donor. Fortunately, experience with matched, unrelated transplants is rapidly increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/48,63,64\">",
"     48,63,64",
"    </a>",
"    ]. An International Bone Marrow Transplant Registry report described the outcome of 151 HLA-identical sibling transplants and 48 alternate related or unrelated transplants performed between 1978 and 1994 by 42 transplant teams [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/63\">",
"     63",
"    </a>",
"    ]. Conditioning regimens were varied and were divided into three main categories according to the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (CTX) dose and radiation schedule:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low dose CTX with or without ATG and limited field radiation",
"     </li>",
"     <li>",
"      Low dose CTX with TBI",
"     </li>",
"     <li>",
"      High dose CTX with or without ATG and no radiation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The five-year survival rates were 66 percent with HLA-identical sibling transplants and 29 percent with alternative donor transplants. The outcomes were significantly worse with older age and lower pretransplant platelet counts, mostly because of increased graft failure and chronic GVHD; the platelet counts were inversely correlated to the number of transfusions before transplant. These adverse effects of increasing age and number of transfusions favor earlier intervention, especially when a matched sibling donor is available.",
"   </p>",
"   <p>",
"    The transplant regimen also had an impact on outcome. The use of ATG had a favorable effect with less acute GVHD and less chronic GVHD. In addition, patients receiving low-dose CTX had a lower risk of treatment failure than did those receiving high-dose CTX and, as expected, the risk of graft failure was higher in unrelated transplants than in matched sibling transplants.",
"   </p>",
"   <p>",
"    The European Group for Blood and Marrow Transplantation published outcomes in 69 patients with FA who underwent transplants from matched unrelated donors utilizing lower-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (20 to 45",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    total dose) plus total abdominal or total body irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/48\">",
"     48",
"    </a>",
"    ]. The three-year probability of survival was 33 percent, and the day-100 transplant-related mortality was 39 percent. The primary causes of death were acute GVHD, primary or secondary graft failure, chronic GVHD, infection, and hepatic veno-occlusive disease. Among the 14 patients older than 15 years of age at the time of transplant only two were alive at last follow-up, yielding a three-year estimated survival of 14 percent. A positive recipient cytomegalovirus serology and the use of androgens before transplant were associated with a worse outcome.",
"   </p>",
"   <p>",
"    Other findings included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary graft failures were observed more frequently when female donors were used, mainly because the grafts contained fewer total nucleated cells than did grafts from male donors.",
"     </li>",
"     <li>",
"      The overall probability of developing grade II to IV and grade III to IV GVHD was 43 and 34 percent, respectively. The incidence of GVHD was higher in patients with extensive malformations, especially limb, urogenital tract, or renal abnormalities.",
"     </li>",
"     <li>",
"      The risk of GVHD was lower in T-cell depleted grafts; this benefit was offset by increased graft failure, resulting in no difference in survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Fludarabine-containing regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early non-randomized studies have suggested that patients with FA receiving alternative donor HCT may do well when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    is part of the conditioning regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/65-69\">",
"     65-69",
"    </a>",
"    ]. Two examples are presented below:",
"   </p>",
"   <p>",
"    A pilot study using a conditioning regimen of low-dose irradiation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and ATG followed by allogeneic HCT using alternative donors (eg, matched unrelated donor or partially matched related or unrelated donor) was undertaken in 27 patients with FA [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/65\">",
"     65",
"    </a>",
"    ]. At a median follow-up of 37 months, overall survival was 96 percent. Toxicity was minimal; grade III-IV acute GVHD occurred in two patients and one patient died of sepsis on day 4.",
"   </p>",
"   <p>",
"    A retrospective analysis of data reported to the Center for International Blood and Marrow Transplant Research evaluated the impact of potential prognostic factors on hematopoietic recovery, GVHD, and mortality in 98 FA recipients of unrelated bone marrow transplants between 1990 and 2003. Results included [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/66\">",
"     66",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Probabilities of neutrophil (89 versus 69 percent) and platelet recovery (74 versus 23 percent) were higher after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      -containing conditioning regimens (compared to non-fludarabine-containing regimens). Of the patients receiving fludarabine, most received a fairly uniform regimen including single fraction total body irradiation (450 cGy) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (20 or 40",
"      <span class=\"nowrap\">",
"       mg/kg).",
"      </span>",
"     </li>",
"     <li>",
"      Risks of acute GVHD were higher when the bone marrow graft was not T-cell depleted (relative risk 4.3)",
"     </li>",
"     <li>",
"      The 100 day mortality rate was significantly lower with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      -containing regimens (24 versus 65 percent)",
"     </li>",
"     <li>",
"      Three-year overall survivals were significantly higher with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      -containing regimens (52 versus 13 percent)",
"     </li>",
"     <li>",
"      Mortality was also higher in recipients who were &gt;10 years of age, were CMV positive, and who had received &gt;20 blood product transfusions before bone marrow transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two major conclusions were reached from this retrospective analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/66\">",
"     66",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      -containing conditioning regimens in the context of T-cell depleted bone marrow allografts might be better for those FA patients unable to tolerate conventional chemotherapy.",
"     </li>",
"     <li>",
"      Consideration should be given to earlier referral for transplantation before excessive transfusions have been employed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     USE OF UMBILICAL CORD BLOOD FOR TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Umbilical cord blood is a rich source of hematopoietic stem cells with high proliferative capacity. Transplantation of hematopoietic cord blood cells obtained from neonatal siblings or unrelated donors can reconstitute the hematopoietic system in patients treated with myeloablative therapies for genetic diseases or malignancies and in patients with primary immunodeficiencies. In addition, transplantation of cord blood from HLA-identical siblings, as compared to HLA-identical sibling bone marrow or peripheral blood transplantation, appears to be associated with a lower risk of acute GVHD (relative risk 41 percent) and chronic GVHD (relative risk 35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H15#H15\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'Umbilical cord blood donors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11002?source=see_link\">",
"     \"Collection and storage of umbilical cord blood for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the first successful cord blood transplant was performed in a patient with FA [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/71\">",
"     71",
"    </a>",
"    ], its role in bone marrow failure syndromes, especially aplastic anemia, needs to be defined. Data reported to an international cord blood transplant registry from 22 transplant centers on 74 matched sibling transplants showed an engraftment rate of approximately 90 percent, with graft failure occurring mostly in patients who had transplants for bone marrow failure syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The EUROCORD Registry reported similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/73\">",
"     73",
"    </a>",
"    ]. Among 562 recipients of cord blood transplants from unrelated donors, a significantly higher risk of graft failure occurred in patients with SAA and FA than in those transplanted for other disorders (36 to 37 versus 16 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The number of patients with bone marrow failure disorders is too small in these series to draw any definite conclusions. At present, the role of cord blood transplantation as initial treatment for SAA or FA, or as a salvage regimen for those who have failed an initial allogeneic transplant, is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The advent of single-cell polymerase chain reaction techniques has presented the opportunity for combined preimplantation genetic diagnosis and HLA antigen testing. This has resulted in the ability to preselect embryos unaffected by FA that can also become HLA-compatible donors of umbilical cord blood stem cells for an affected sibling with FA [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/76\">",
"     76",
"    </a>",
"    ]. The ethical issues associated with such a strategy are, and will continue to be, the focus of debate [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     LONG-TERM OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The late effects after HCT for aplastic anemia have been evaluated in two large series. A retrospective analysis described the outcomes of 212 patients with aplastic anemia who were transplanted in Seattle between 1970 and 1993 and who survived for at least two years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/78\">",
"     78",
"    </a>",
"    ]. Chronic GVHD emerged as a dominant risk factor for late complications. Survival probabilities at 20 years were 69 and 89 percent for patients with and without chronic GVHD, respectively. Seventeen patients died at 2 to 20 years post-transplant; 13 of them (76 percent) had chronic GVHD. In addition, carcinoma of the oropharyngeal mucosa occurred exclusively in patients with chronic GVHD.",
"   </p>",
"   <p>",
"    Other complications included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Depression &mdash; 19 percent",
"     </li>",
"     <li>",
"      Bone and joint problems &mdash; 18 percent",
"     </li>",
"     <li>",
"      Skin problems &mdash; 14 percent",
"     </li>",
"     <li>",
"      Cataracts &mdash; 12 percent",
"     </li>",
"     <li>",
"      Solid tumor malignancy &mdash; 12 percent (mostly squamous cell carcinoma)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An encouraging observation from this study was that at 2 years post-transplant, approximately 83 percent of patients had returned to school or work; this number increased to 90 percent by 20 years. Patients rated their quality of life as excellent and symptoms as minimal or mild, and the majority of those surviving beyond 2 years returned to a fully functional life.",
"   </p>",
"   <p>",
"    A second publication from the Seattle group described late effects among 152 children with aplastic anemia who survived for more than one year post-HCT and were followed for a median of 21.8 years (range: 1 to 38) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Estimated 30-years survivals were 82 and 58 percent for those transplanted for idiopathic aplastic anemia or Fanconi anemia, respectively. Risk factors negatively impacting survival were chronic GVHD and Fanconi anemia.",
"     </li>",
"     <li>",
"      Quality of life studies in 49 adult HCT survivors indicated they were comparable to controls except for their being denied health (18 versus 2 percent) and life (20 versus 1 percent) insurance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Late Effects Working Committee of the International Bone Marrow Transplant Registry studied 1029 patients with aplastic anemia who were treated with allogeneic HCT between 1980 and 1993 and who were alive and free of aplastic anemia for at least two years after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/80\">",
"     80",
"    </a>",
"    ]. At a median follow-up of 11 years, 60 patients had died (5.8 percent). The causes of death were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      GVHD &mdash; 38 patients",
"     </li>",
"     <li>",
"      Infection without GVHD &mdash; 7 patients",
"     </li>",
"     <li>",
"      Organ failure (liver, cardiac, pulmonary, renal) &mdash; 5 patients",
"     </li>",
"     <li>",
"      Other (hemorrhage, interstitial pneumonia, drug reaction, miscellaneous) &mdash; 7 patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative risks for late death were 4.5, 3.0, 2.2, and 2.1 for the presence of active chronic GVHD at two years, delayed time to transplant (&gt;1 year), history of acute GVHD, and resolved chronic GVHD at two years, respectively. A Karnofsky performance score of less than 90 percent (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"     table 1",
"    </a>",
"    ) was noted in 12 percent of survivors in this group. Of special interest were the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No cases of relapse of aplastic anemia occurred",
"     </li>",
"     <li>",
"      The incidence of new cancer was 2 percent (one patient)",
"     </li>",
"     <li>",
"      The risk of death by the sixth year post-transplant did not differ significantly from that of a normal population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Secondary graft failure usually occurs within 100 days after HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/81\">",
"     81",
"    </a>",
"    ], although it has been reported in two patients 8 and 10 years post-HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Examination of bone marrow in both instances revealed mixed chimerism, with 75 to 85 percent of hematopoietic cells being of donor origin. Both patients were successfully retransplanted from the original donor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Late malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant long-term problem after successful treatment for both SAA and FA has been the development of new malignancies. Clonal and myeloproliferative disorders appear to be more common with immunosuppressive therapy. A report from the Severe Aplastic Anaemia Working Party of the European Blood and Marrow Transplantation estimated a 10-year incidence of malignancy, mostly myelodysplastic syndrome (MDS) or acute leukemia, of 19 percent in 860 patients treated with immunosuppressive therapy (5.2 times the overall cancer risk in an age-matched population) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/84\">",
"     84",
"    </a>",
"    ]. A much lower value, 3 percent, consisting primarily of solid tumors, was seen after HCT. The incidence of solid tumors was similar with the two procedures, but hematologic malignancy was much less common after bone marrow transplantation. The latter finding in part reflects the increased risk of MDS and acute leukemia associated with FA itself [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link&amp;anchor=H4#H4\">",
"     \"Inherited aplastic anemia in children\", section on 'Fanconi anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another report analyzed 700 patients transplanted for SAA or FA in Seattle or Paris [",
"    <a class=\"abstract\" href=\"UTD.htm?11/18/11562/abstract/86\">",
"     86",
"    </a>",
"    ]. Twenty-three patients developed a malignancy at a median of 91 months after the transplant. They included five lymphoid malignancies (which occurred early; median, three months) and 18 solid tumors (which occurred late; median, 99 months). The Kaplan-Meier estimate of the malignancy risk was 14 percent at 20 years. Risk factors for solid tumors identified in univariate analysis included the underlying diagnosis of FA,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    therapy for chronic GVHD, and radiation therapy (TBI or total abdominal irradiation) in the preparative regimen. No case of myeloproliferative disease was observed.",
"   </p>",
"   <p>",
"    In multivariate, stepwise proportional hazards models,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    therapy and the diagnosis of FA were significant risk factors for all patients. If only non-Fanconi patients were considered, azathioprine therapy, age, and irradiation were significant factors. Because azathioprine is no longer routinely used in the treatment of GVHD and conditioning regimens that do not use irradiation are now the standard for matched sibling transplants, a reasonable expectation is that the risk of new malignancies will decrease in subsequent cohorts of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23522714\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23522760\">",
"    <span class=\"h2\">",
"     Severe aplastic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic hematopoietic cell transplantation (HCT) from an HLA-identical sibling donor is the treatment of choice for a child with severe aplastic anemia (SAA), offering a cure by restoration of normal hematopoiesis. Long-term survival (currently &ge;90 percent) has been achieved by the following (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Idiopathic severe aplastic anemia'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A reduction in the incidence, severity, and mortality from acute graft-versus-host disease",
"     </li>",
"     <li>",
"      A reduction in the incidence of marrow graft rejection",
"     </li>",
"     <li>",
"      Early transplantation before the onset of severe infections",
"     </li>",
"     <li>",
"      Avoidance of blood product transfusions from the proposed HCT donor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If an HLA-matched donor is not immediately available, children with SAA should receive immediate treatment with an immunosuppressive regimen. A search for an HLA-matched unrelated donor can be initiated at that time, with the expectation that the outcome following an HLA-identical unrelated donor transplant in children with SAA is comparable to that from an HLA-identical sibling donor. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Alternatives to allogeneic HCT'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23522797\">",
"    <span class=\"h2\">",
"     Fanconi anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of children with Fanconi anemia consists of supportive modalities, androgens, and hematopoietic growth factors, which can achieve a transient improvement in hematopoietic function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link&amp;anchor=H4#H4\">",
"     \"Inherited aplastic anemia in children\", section on 'Fanconi anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For those refractory or intolerant to such treatment who have developed severe bone marrow failure, myelodysplasia, or acute myeloid leukemia, allogeneic HCT is the only treatment option that can restore normal hematopoiesis. If an HLA-identical sibling donor (the best choice) is not available, children receiving HCT from an HLA-matched unrelated donor may do well when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    is part of the conditioning regimen. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Fanconi anemia'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/1\">",
"      Rozman C, Mar&iacute;n P, Nomdedeu B, Montserrat E. Criteria for severe aplastic anaemia. Lancet 1987; 2:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/2\">",
"      Young NS, Barrett AJ. The treatment of severe acquired aplastic anemia. Blood 1995; 85:3367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/3\">",
"      Davies JK, Guinan EC. An update on the management of severe idiopathic aplastic anaemia in children. Br J Haematol 2007; 136:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/4\">",
"      Storb R. Bone marrow transplantation for aplastic anemia. Cell Transplant 1993; 2:365.",
"     </a>",
"    </li>",
"    <li>",
"     European Group of Bone Marrow Transplant. Severe aplastic anaemia working party. In: EBMT Working Parties Reports, 49, Harrogate, UK, 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/6\">",
"      Patel SR, Cadwell CM, Medford A, Zimring JC. Transfusion of minor histocompatibility antigen-mismatched platelets induces rejection of bone marrow transplants in mice. J Clin Invest 2009; 119:2787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/7\">",
"      Storb R, Etzioni R, Anasetti C, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/8\">",
"      Stucki A, Leisenring W, Sandmaier BM, et al. Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis). Blood 1998; 92:2742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/9\">",
"      Casper JT, Truitt RR, Baxter-Lowe LA, Ash RC. Bone marrow transplantation for severe aplastic anemia in children. Am J Pediatr Hematol Oncol 1990; 12:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/10\">",
"      Sanders JE, Storb R, Anasetti C, et al. Marrow transplant experience for children with severe aplastic anemia. Am J Pediatr Hematol Oncol 1994; 16:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/11\">",
"      Bacigalupo A, Hows J, Gluckman E, et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. Br J Haematol 1988; 70:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/12\">",
"      Arranz R, Otero MJ, Ramos R, et al. Clinical results in 50 multiply transfused patients with severe aplastic anemia treated with bone marrow transplantation or immunosuppressive therapy. Bone Marrow Transplant 1994; 13:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/13\">",
"      Inagaki J, Nagatoshi Y, Kawano Y, et al. Bone marrow transplantation in children with severe aplastic anemia using a conditioning regimen containing 3 Gy of total body irradiation, cyclophosphamide with or without antithymocyte globulin. Pediatr Transplant 2007; 11:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/14\">",
"      Burroughs LM, Woolfrey AE, Storer BE, et al. Success of allogeneic marrow transplantation for children with severe aplastic anaemia. Br J Haematol 2012; 158:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/15\">",
"      Samarasinghe S, Steward C, Hiwarkar P, et al. Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience. Br J Haematol 2012; 157:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/16\">",
"      Lawler M, McCann SR, Marsh JC, et al. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA. Br J Haematol 2009; 144:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/17\">",
"      Bross DS, Tutschka PJ, Farmer ER, et al. Predictive factors for acute graft-versus-host disease in patients transplanted with HLA-identical bone marrow. Blood 1984; 63:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/18\">",
"      Weisdorf D, Hakke R, Blazar B, et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991; 51:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/19\">",
"      Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/20\">",
"      Sobocinski KA, Horowitz MM, Rowlings PA, et al. Bone marrow transplantation--1994: a report from the International Bone Marrow Transplant Registry and the North American Autologous Bone Marrow Transplant Registry. J Hematother 1994; 3:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/21\">",
"      Ades L, Mary JY, Robin M, et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood 2004; 103:2490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/22\">",
"      Kobayashi R, Yabe H, Hara J, et al. Preceding immunosuppressive therapy with antithymocyte globulin and ciclosporin increases the incidence of graft rejection in children with aplastic anaemia who underwent allogeneic bone marrow transplantation from HLA-identical siblings. Br J Haematol 2006; 135:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/23\">",
"      Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. Blood 1996; 87:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/24\">",
"      Meyers G, Maziarz RT. Is it time for a change? The case for early application of unrelated allo-SCT for severe aplastic anemia. Bone Marrow Transplant 2010; 45:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/25\">",
"      Kosaka Y, Yagasaki H, Sano K, et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood 2008; 111:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/26\">",
"      Clift RA, Hansen JA, Thomas ED, et al. Marrow transplantation from donors other than HLA-identical siblings. Transplantation 1979; 28:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/27\">",
"      Hows JM, Yin JL, Marsh J, et al. Histocompatible unrelated volunteer donors compared with HLA nonidentical family donors in marrow transplantation for aplastic anemia and leukemia. Blood 1986; 68:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/28\">",
"      Davies SM, Shu XO, Blazar BR, et al. Unrelated donor bone marrow transplantation: influence of HLA A and B incompatibility on outcome. Blood 1995; 86:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/29\">",
"      Hongeng S, Krance RA, Bowman LC, et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet 1997; 350:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/30\">",
"      Kojima S, Inaba J, Yoshimi A, et al. Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation. Br J Haematol 2001; 114:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/31\">",
"      Vassiliou GS, Webb DK, Pamphilon D, et al. Improved outcome of alternative donor bone marrow transplantation in children with severe aplastic anaemia using a conditioning regimen containing low-dose total body irradiation, cyclophosphamide and Campath. Br J Haematol 2001; 114:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/32\">",
"      Kennedy-Nasser AA, Leung KS, Mahajan A, et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant 2006; 12:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/33\">",
"      Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 1998; 339:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/34\">",
"      Nademanee A, Schmidt GM, Parker P, et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 1995; 86:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/35\">",
"      Nash RA, Pi&ntilde;eiro LA, Storb R, et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood 1996; 88:3634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/36\">",
"      Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/37\">",
"      Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/38\">",
"      Margolis D, Camitta B, Pietryga D, et al. Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults. Br J Haematol 1996; 94:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/39\">",
"      Deeg HJ, O'Donnell M, Tolar J, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 2006; 108:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/40\">",
"      Perez-Albuerne ED, Eapen M, Klein J, et al. Outcome of unrelated donor stem cell transplantation for children with severe aplastic anemia. Br J Haematol 2008; 141:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/41\">",
"      Gupta V, Ball SE, Sage D, et al. Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning. Bone Marrow Transplant 2005; 35:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/42\">",
"      Marsh JC, Gupta V, Lim Z, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood 2011; 118:2351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/43\">",
"      Schrezenmeier H, Marin P, Raghavachar A, et al. Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party. Br J Haematol 1993; 85:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/44\">",
"      Lawlor ER, Anderson RA, Davis JH, et al. Immunosuppressive therapy: a potential alternative to bone marrow transplantation as initial therapy for acquired severe aplastic anemia in childhood? J Pediatr Hematol Oncol 1997; 19:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/45\">",
"      Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 2000; 95:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/46\">",
"      Cervenka J, Arthur D, Yasis C. Mitomycin C test for diagnostic differentiation of idiopathic aplastic anemia and Fanconi anemia. Pediatrics 1981; 67:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/47\">",
"      Mehta P, Locatelli F, Stary J, Smith FO. Bone marrow transplantation for inherited bone marrow failure syndromes. Pediatr Clin North Am 2010; 57:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/48\">",
"      Guardiola P, Pasquini R, Dokal I, et al. Outcome of 69 allogeneic stem cell transplantations for Fanconi anemia using HLA-matched unrelated donors: a study on behalf of the European Group for Blood and Marrow Transplantation. Blood 2000; 95:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/49\">",
"      Alter BP, Caruso JP, Drachtman RA, et al. Fanconi anemia: myelodysplasia as a predictor of outcome. Cancer Genet Cytogenet 2000; 117:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/50\">",
"      Mehta PA, Ileri T, Harris RE, et al. Chemotherapy for myeloid malignancy in children with Fanconi anemia. Pediatr Blood Cancer 2007; 48:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/51\">",
"      Gluckman E, Berger R, Dutreix J. Bone marrow transplantation for Fanconi anemia. Semin Hematol 1984; 21:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/52\">",
"      Guardiola P, Soci&eacute; G, Li X, et al. Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: risk factors and influence on outcome. Blood 2004; 103:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/53\">",
"      Gluckman E, Devergie A, Dutreix J. Radiosensitivity in Fanconi anaemia: application to the conditioning regimen for bone marrow transplantation. Br J Haematol 1983; 54:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/54\">",
"      Gluckman E. Radiosensitivity in Fanconi anemia: application to the conditioning for bone marrow transplantation. Radiother Oncol 1990; 18 Suppl 1:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/55\">",
"      Flowers ME, Zanis J, Pasquini R, et al. Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation. Br J Haematol 1996; 92:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/56\">",
"      Kohli-Kumar M, Morris C, DeLaat C, et al. Bone marrow transplantation in Fanconi anemia using matched sibling donors. Blood 1994; 84:2050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/57\">",
"      Medeiros C, Zanis-Neto J, Pasquini R. Bone marrow transplantation for patients with Fanconi anemia: reduced doses of cyclophosphamide without irradiation as conditioning. Bone Marrow Transplant 1999; 24:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/58\">",
"      Soci&eacute; G, Devergie A, Girinski T, et al. Transplantation for Fanconi's anaemia: long-term follow-up of fifty patients transplanted from a sibling donor after low-dose cyclophosphamide and thoraco-abdominal irradiation for conditioning. Br J Haematol 1998; 103:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/59\">",
"      Dufour C, Rondelli R, Locatelli F, et al. Stem cell transplantation from HLA-matched related donor for Fanconi's anaemia: a retrospective review of the multicentric Italian experience on behalf of AIEOP-GITMO. Br J Haematol 2001; 112:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/60\">",
"      Farzin A, Davies SM, Smith FO, et al. Matched sibling donor haematopoietic stem cell transplantation in Fanconi anaemia: an update of the Cincinnati Children's experience. Br J Haematol 2007; 136:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/61\">",
"      Ayas M, Al-Jefri A, Al-Seraihi A, et al. Allogeneic stem cell transplantation in Fanconi anemia patients presenting with myelodysplasia and/or clonal abnormality: update on the Saudi experience. Bone Marrow Transplant 2008; 41:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/62\">",
"      Zanis-Neto J, Flowers ME, Medeiros CR, et al. Low-dose cyclophosphamide conditioning for haematopoietic cell transplantation from HLA-matched related donors in patients with Fanconi anaemia. Br J Haematol 2005; 130:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/63\">",
"      Gluckman E, Auerbach AD, Horowitz MM, et al. Bone marrow transplantation for Fanconi anemia. Blood 1995; 86:2856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/64\">",
"      MacMillan ML, Auerbach AD, Davies SM, et al. Haematopoietic cell transplantation in patients with Fanconi anaemia using alternate donors: results of a total body irradiation dose escalation trial. Br J Haematol 2000; 109:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/65\">",
"      Yabe H, Inoue H, Matsumoto M, et al. Allogeneic haematopoietic cell transplantation from alternative donors with a conditioning regimen of low-dose irradiation, fludarabine and cyclophosphamide in Fanconi anaemia. Br J Haematol 2006; 134:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/66\">",
"      Wagner JE, Eapen M, MacMillan ML, et al. Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood 2007; 109:2256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/67\">",
"      Chaudhury S, Auerbach AD, Kernan NA, et al. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia. Br J Haematol 2008; 140:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/68\">",
"      Thakar MS, Kurre P, Storb R, et al. Treatment of Fanconi anemia patients using fludarabine and low-dose TBI, followed by unrelated donor hematopoietic cell transplantation. Bone Marrow Transplant 2011; 46:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/69\">",
"      Thakar MS, Bonfim C, Sandmaier BM, et al. Cyclophosphamide-based in vivo T-cell depletion for HLA-haploidentical transplantation in Fanconi anemia. Pediatr Hematol Oncol 2012; 29:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/70\">",
"      Rocha V, Wagner JE Jr, Sobocinski KA, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 2000; 342:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/71\">",
"      Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989; 321:1174.",
"     </a>",
"    </li>",
"    <li>",
"     Wagner JE, Kurtzberg J. Allogeneic umbilical cord blood transplant. In: Cellular Characteristics of Cord Blood and Cord Blood Transplantation, Broxmeyer HE (Ed), AABB Press, Bethesda 1998. p.113.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/73\">",
"      Gluckman E, Rocha V, Chammard AB, et al. Results of cord blood transplants in Europe (abstract). Blood 1996; 88:485a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/74\">",
"      Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/75\">",
"      Ruggeri A, de Latour RP, Rocha V, et al. Double cord blood transplantation in patients with high risk bone marrow failure syndromes. Br J Haematol 2008; 143:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/76\">",
"      Verlinsky Y, Rechitsky S, Schoolcraft W, et al. Preimplantation diagnosis for Fanconi anemia combined with HLA matching. JAMA 2001; 285:3130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/77\">",
"      Damewood MD. Ethical implications of a new application of preimplantation diagnosis. JAMA 2001; 285:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/78\">",
"      Deeg HJ, Leisenring W, Storb R, et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood 1998; 91:3637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/79\">",
"      Sanders JE, Woolfrey AE, Carpenter PA, et al. Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia. Blood 2011; 118:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/80\">",
"      Soci&eacute; G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999; 341:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/81\">",
"      Appelbaum FR, Cheever MA, Fefer A, et al. Recurrence of aplastic anemia following cyclophosphamide and syngeneic bone marrow transplantation: evidence for two mechanisms of graft failure. Blood 1985; 65:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/82\">",
"      Dufour C, Dallorso S, Casarino L, et al. Late graft failure 8 years after first bone marrow transplantation for severe acquired aplastic anemia. Bone Marrow Transplant 1999; 23:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/83\">",
"      Eapen M, Davies SM, Ramsay NK. Late graft rejection and second infusion of bone marrow in children with aplastic anaemia. Br J Haematol 1999; 104:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/84\">",
"      Soci&eacute; G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med 1993; 329:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/85\">",
"      Butturini A, Gale RP, Verlander PC, et al. Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. Blood 1994; 84:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/18/11562/abstract/86\">",
"      Deeg HJ, Soci&eacute; G, Schoch G, et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996; 87:386.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3534 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-7BCA055868-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_18_11562=[""].join("\n");
var outline_f11_18_11562=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23522714\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IDIOPATHIC SEVERE APLASTIC ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Graft rejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10343810\">",
"      Outcome following transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Reappearance of recipient-derived cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Alternatives to allogeneic HCT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - HCT from matched unrelated donors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FANCONI ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hypersensitivity to routine conditioning agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cyclophosphamide-containing regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - HLA-identical related donors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Alternative donors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Fludarabine-containing regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      USE OF UMBILICAL CORD BLOOD FOR TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      LONG-TERM OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Late malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23522714\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23522760\">",
"      Severe aplastic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23522797\">",
"      Fanconi anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/3534\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3534|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 1\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=related_link\">",
"      Acquired aplastic anemia in children and young adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11002?source=related_link\">",
"      Collection and storage of umbilical cord blood for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17030?source=related_link\">",
"      Hematopoietic cell transplantation for Diamond-Blackfan anemia and the myelodysplastic syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=related_link\">",
"      Inherited aplastic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18826?source=related_link\">",
"      Pathogenesis of graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=related_link\">",
"      Prevention and treatment of acute graft-versus-host disease: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_18_11563="Disorders associated globus";
var content_f11_18_11563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disorders associated with globus sensation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Abnormal esophageal body or lower esophageal sphincter motility",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Achalasia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       After uvulopalatoplasty",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Carcinoma of the base of the tongue",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cervical lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Esophageal inlet patch",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gastroesophageal reflux disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gastroduodenal lesions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Goiter",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hiatal hernia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypertensive upper esophageal sphincter",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hyperplastic tonsils",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Paraesophageal masses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Postcricoid webs",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_18_11563=[""].join("\n");
var outline_f11_18_11563=null;
var title_f11_18_11564="Durie Salmon staging system";
var content_f11_18_11564=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F56890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F56890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Durie-Salmon staging system for multiple myeloma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Stage I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low cell mass: &lt;0.6 x 10",
"        <sup>",
"         12",
"        </sup>",
"        cells/m",
"        <sup>",
"         2",
"        </sup>",
"        &nbsp;",
"        <strong>",
"         PLUS",
"        </strong>",
"        all of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hgb &gt;10 g/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum IgG &lt;5 g/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum IgA &lt;3 g/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal serum calcium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine monoclonal protein excretion &lt;4 g/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No generalized lytic bone lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Stage II",
"       </td>",
"      </tr>",
"      <tr>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intermediate cell mass: neither stage I nor stage III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Stage III",
"       </td>",
"      </tr>",
"      <tr>",
"      </tr>",
"      <tr>",
"       <td>",
"        High cell mass: &gt;1.2 x 10",
"        <sup>",
"         12",
"        </sup>",
"        cells/m",
"        <sup>",
"         2",
"        </sup>",
"        <strong>",
"         PLUS",
"        </strong>",
"        one of more of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hgb &lt;8.5 g/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum IgG &gt;7 g/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum IgA &gt;5 g/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum calcium &gt;12 mg/dL (3 &mu;mol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine monoclonal protein excretion &gt;12 g/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Advanced lytic bone lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Stage III is subclassified&nbsp;as IIIA&nbsp;or IIIB based on serum creatinine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. Serum creatinine &lt;2 mg/dL (177 &mu;mol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. Serum creatinine &ge;2 mg/dL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Hgb: hemoglobin; IgG: immunoglobulin G; IgA: immunoglobulin A",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_18_11564=[""].join("\n");
var outline_f11_18_11564=null;
var title_f11_18_11565="Sulfite-containing foods";
var content_f11_18_11565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F66943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F66943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sulfite-containing foods",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            High content",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dried fruit (excluding dark raisins and prunes)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lemon juice (nonfrozen)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lime juice (nonfrozen)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Wine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Molasses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sauerkraut juice",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Grape juice (white, white sparkling, pink sparkling, red sparkling)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Moderate content",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dried potatoes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Wine vinegar",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gravies, sauces",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fruit topping",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Maraschino cherries",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pectin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Shrimp (fresh)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sauerkraut",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pickled peppers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pickled cocktail onions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pickles/relishes",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Low content (&lt;10 ppm)*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Corn starch",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hominy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Frozen potatoes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Maple syrup",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Imported jams and jellies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fresh mushrooms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Malt vinegar",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dried cod",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Canned potatoes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Beer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dry soup mix",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Soft drinks",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Instant tea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pizza dough (frozen)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pie dough",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sugar (especially beet sugar)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gelatin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Coconut",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fresh fruit salad",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Domestic jams and jellies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Crackers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cookies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Grapes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            High fructose corn syrup",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Foods with low sulfite content have not been implicated in inducing reactions in sulfite-sensitive individuals.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ronald A Simon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_18_11565=[""].join("\n");
var outline_f11_18_11565=null;
var title_f11_18_11566="AP xray of middle phalanx oblique fracture";
var content_f11_18_11566=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oblique fracture of the middle phalanx: AP view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 156px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This radiograph shows an oblique fracture of the middle phalanx. Note the slight displacement at the distal end of the fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_18_11566=[""].join("\n");
var outline_f11_18_11566=null;
var title_f11_18_11567="Chronic SVT management children";
var content_f11_18_11567=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 616px\">",
"   <div class=\"ttl\">",
"    Chronic management of SVT in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 596px; height: 570px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SVT: supraventricular tachycardia.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_18_11567=[""].join("\n");
var outline_f11_18_11567=null;
